

UC Office of the President

Report to California Legislature

Title

Analysis of California Assembly Bill 575: Obesity Prevention Treatment Parity Act

Permalink

<https://escholarship.org/uc/item/9028h859>

Journal

Report to California Legislature

Author

California Health Benefits Review Program


Publication Date

2025-04-22

DOI

10.13140/RG.2.2.14916.08322

Peer reviewed



A REPORT TO THE 2025–2026 CALIFORNIA LEGISLATURE

Analysis of California Assembly Bill 575: Obesity Prevention Treatment Parity Act

APRIL 22, 2025



California Health Benefits Review Program (CHBRP)
University of California, Berkeley

chbrp.org

Analysis of California Assembly Bill 575

Obesity Prevention Treatment Parity Act

Summary to the 2025–2026 California State Legislature April 22, 2025



Summary

The version of California Assembly Bill (AB) 575 analyzed by California Health Benefits Review Program (CHBRP) would require coverage without prior authorization for intensive behavioral therapy (IBT) and at least one glucagon-like peptide-1 (GLP-1) anti-obesity medication (AOM) for the treatment or prevention of obesity.

In 2026, of the 22.2 million Californians enrolled in state-regulated health insurance, 13.6 million of them would have insurance subject to AB 575.

Benefit Coverage

At baseline, nearly all the population with health insurance subject to AB 575 has coverage for IBT (99.8% enrollees). Approximately 17.4% of enrollees have coverage for GLP-1 AOMs. Postmandate, 100% would have coverage for both treatments. AB 575 would likely not exceed essential health benefits (EHBs).

Medical Effectiveness

CHBRP found *very strong evidence* that IBT is effective in reducing weight and improving related health outcomes in adults, adolescents, and children. There is *very strong evidence* that U.S. Food and Drug Administration (FDA)-approved GLP-1 AOMs are effective in reducing weight in adults, and *conflicting evidence* that they are effective in reducing weight in children and adolescents.

Cost and Health Impacts¹

In Year 1 (2026), CHBRP estimates that AB 575 would result in an additional 182,520 enrollees using FDA-approved GLP-1 AOMs and 35 enrollees receiving IBT. These enrollees would experience a 5% to 21% reduction in body weight, and related health improvements.

AB 575 would increase total premiums by approximately \$1 billion in the first year postmandate. In addition, CHBRP estimates that cost sharing would increase by approximately \$153 million. Enactment of AB 575 would also reduce previously noncovered expenses by approximately \$256 million.

In Year 2, increases in utilization would continue to impact premiums for a total of approximately \$1.5 billion, resulting in greater than 1% increase in all but one market segment. CHBRP estimates this would lead to 12,600 newly uninsured Californians. Assuming persistent use of GLP-1 medications, CHBRP estimates that medical costs for each GLP-1 user would decrease by \$100 due to a reduction in risk of heart failure after 12 to 18 months of treatment.

Context

Obesity is a chronic health condition characterized by an increase in the size and amount of fat cells in the body.² Health care providers screen for obesity by calculating patients' body mass index (BMI), which takes into account an individual's height and weight. Adults with a BMI of 25 or higher are categorized as overweight, and those with a BMI of 30 or higher are categorized as obese.

There are many health consequences of obesity, such as an increased risk of heart disease, diabetes, respiratory issues, musculoskeletal disorders, and certain cancers, as well as reduced life expectancy.

There are several methods used to treat obesity. AB 575 focuses on two treatment types: intensive behavioral therapy (IBT) and glucagon-like peptide-1 (GLP-1) anti-obesity medications (AOMs).

- **IBT** is a particular form of behavioral intervention that is structured and has several components. Patients are provided with tools to support and

¹ Similar cost and health impacts could be expected for the following year, though possible changes in medical science and other aspects of health make stability of impacts less certain as time goes by.

² Refer to CHBRP's full report for full citations and references.

maintain weight loss (e.g., food scales, pedometers).

- **GLP-1 AOMs**, also known as glucagon-like peptide-1 (GLP-1) receptor agonists are a class of drugs that activate the body's GLP-1 receptors. This activation triggers several downstream effects, including lowering glucose (sugar) levels within the bloodstream, reducing digestion rate, and increasing the sensation of fullness for longer. GLP-1 medications are indicated for type 2 diabetes and obesity, among other conditions.

Bill Summary

AB 575 would require coverage without prior authorization for intensive behavioral therapy and at least one GLP-1 receptor agonist, for the treatment or prevention of obesity. In addition, the bill would prohibit coverage criteria from being more restrictive than the U.S. Food and Drug Administration (FDA)-approved indications for those treatments.

There are currently no FDA-approved GLP-1 drugs with an indication for obesity prevention. Three FDA-approved GLP-1's are indicated for chronic weight management and are included in this analysis: liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound).


Figure A notes how many Californians have health insurance that would be subject to AB 575.

Impacts

AB 575 requires the coverage of at least one GLP-1 drug for treatment of obesity. CHBRP assumes that health plans and health insurance policies that are noncompliant with the mandate will choose to cover the lowest priced options, which in this case will be the two newer, weekly GLP-1 drugs (Wegovy and Zepbound). Because Saxenda, which is also manufactured by the same company that makes Wegovy (Novo Nordisk) has been on the market longer, is a daily regimen, has more side effects than Zepbound, and maintains a higher price

point, CHBRP assumes that health plans and insurance policies will not rely on Saxenda to comply with AB 575.

Figure A. Health Insurance in CA and AB 575.



Source: California Health Benefits Review Program, 2025.

Note: CHBRP generally assumes alignment of Medi-Cal Managed Care plan benefits, with limited exceptions.³

Key: CDI = California Department of Insurance; COHS = County Organized Health System; DHCS = Department of Health Care Services; DMHC = Department of Managed Health Care.

Benefit Coverage

CHBRP estimates that at baseline, 11.21 million Californians (82.6%) with state-regulated insurance subject to the mandate are enrolled in plans or policies that do not currently cover a GLP-1 indicated for chronic weight management, as required by AB 575. Approximately 30,000 enrollees (0.2%) do not have coverage for IBT at baseline.

Utilization

At baseline, CHBRP estimates there are 42,813 enrollees using GLP-1 AOMs without coverage, and zero enrollees receiving IBT without coverage. Postmandate, AB 575 would lead to an increase in utilization of GLP-1 AOMs by approximately 182,520 enrollees. An additional 35 enrollees would receive IBT postmandate.


Managed Care plan contract or the law exempts specified Medi-Cal contracted providers.

³ Although COHS plans are not subject to the Knox-Keene Act, DHCS generally updates Medi-Cal Managed Care plan contracts, All Plan Letters, and other appropriate authorities for alignment of managed care plan benefits, except in cases when the benefit is carved out of the Medi-Cal

Expenditures

CHBRP estimates AB 575 would increase total premiums by approximately \$1 billion in the first year postmandate. In addition, CHBRP estimates that cost sharing would increase by approximately \$153 million. Enactment of AB 575 would also reduce previously noncovered expenses by approximately \$256 million.

Figure B. Expenditure Impacts of AB 575



Source: California Health Benefits Review Program, 2025.
Key: DMHC = Department of Managed Health Care.

Medi-Cal

There would be no impact on Medi-Cal expenditures as AB 575 only applies to group and individual health plans and policies; therefore, it does not apply to the health insurance of any Medi-Cal beneficiaries, including those in managed care plans regulated by DMHC.

CalPERS

For enrollees associated with California Public Employees' Retirement System (CalPERS) in DMHC-regulated plans, premiums would increase by approximately \$62 million (0.79%).

Covered California – Individually Purchased

Premiums would increase by approximately \$140 million (0.89%) for DMHC-regulated Covered California individual market plan enrollees, and mirror plans available to individuals outside of Covered California would see an increase in premiums of approximately \$42.3 million (0.70%).

Number of Uninsured in California

In the first year postmandate, because the change in average premiums does not exceed 1% for any market segment, CHBRP would expect no measurable change in the number of uninsured persons due to the enactment of AB 575. However, the premium increase in Year 2, as additional enrollees obtain GLP-1 drugs will be above 1% in all but one market segment, resulting in an estimated 12,600 newly uninsured people in 2027.

Medical Effectiveness

CHBRP's medical literature review focused on determining the effectiveness of IBT and FDA-approved GLP-1s indicated for chronic weight management on a reduction in the incidence of adult and adolescent obesity and associated health outcomes, compared with no intervention, or in conjunction with another treatment.

Measurable health outcomes relevant to AB 575 include primary outcomes such as change in body weight of 5%, 10%, 15%, or 20%, waist circumference, and mean BMI change. Additional health-related outcomes included diabetes risk, hemoglobin, systolic and diastolic blood pressure, and functional quality of life. CHBRP also reviewed literature on harms of FDA-approved GLP-1s. The results of the literature review are as follows:

- FDA-approved GLP-1s:
 - *Very strong evidence* that use of GLP-1s combined with usual care (including diet and activity and lifestyle recommendations) results in greater weight loss than usual care alone in adults.
 - *Very strong evidence* of improvement in health-related quality of life, physical functioning, and cardiac-related health outcomes in adults.
 - *Conflicting evidence* that GLP-1 AOMs improve weight loss in children and adolescents.
- IBT:
 - *Very strong evidence* that IBT is effective in reducing weight and the risk of developing type 2 diabetes in adults.
 - *Very strong evidence* that IBT is effective for weight management and is associated with greater improvements in diabetes and blood pressure control in adolescents and children.

Public Health

It is estimated that as a result of AB 575, utilization of obesity treatments would increase, with approximately 182,520 enrollees using FDA-approved GLP-1 AOMs and 35 enrollees receiving IBT for weight loss. As a result, these enrollees would experience a 5% to 21% reduction in body weight and related health improvements, which is supported by evidence that obesity treatments are medically effective.

Long-Term Impacts

CHBRP estimates that enrollees would continue to use GLP-1 AOMs to treat obesity due to AB 575. During Year 2 postmandate, additional increases in use will have implications for increases in premiums. CHBRP estimates there would be an approximate \$1.5 billion impact on premiums in Year 2 postmandate, and an increase in cost sharing responsibilities for enrollees of \$226 million. Enrollee expenses for noncovered benefits would decrease by approximately \$385 million.

Public health impacts would be likely to accrue for individuals impacted by AB 575 outside of the first year postmandate, such as the overall presence of obesity

and obesity-related chronic disease (e.g., hypertension, cardiovascular disease, type 2 diabetes, certain cancers, obstructive sleep apnea, liver disease, and neurodegenerative diseases); however, the magnitude of these benefits is unknown. Although GLP-1 use has been shown generate reduction in heart failure/heart attacks between 12 and 18 months of use, there is no current evidence on long-term benefits and reductions in avoidable care. However, GLP-1s appear to hold promise in treating other conditions, including substance use disorders, that may have long-term effects. Over time, additional GLP-1 AOMs may be introduced to market which may have different side effect profiles and additional benefits. Because AB 575 requires coverage of at least one GLP-1 AOM, the per unit cost of the medication may be a factor in adoption by health plans and insurance companies.

Essential Health Benefits and the Affordable Care Act

As the obesity treatments that are the focus of this analysis are regularly covered in the essential health benefit (EHB) benchmark plan, it seems unlikely that AB 575 would exceed the definition of EHBs in California.

About CHBRP

The California Health Benefits Review Program (CHBRP) was established in 2002. As per its authorizing statute, CHBRP provides the California Legislature with independent analysis of the medical, financial, and public health impacts of proposed health insurance benefit-related legislation.

The state funds CHBRP through an annual assessment on health plans and insurers in California.

An analytic staff based at the University of California, Berkeley, supports a task force of faculty and research staff from multiple University of California campuses to complete each CHBRP analysis. A strict conflict-of-interest policy ensures that the analyses are undertaken without bias. An independent actuarial firm, Milliman, helps to estimate the financial impact. Content experts with comprehensive subject-matter expertise are consulted to provide essential background and input on the analytic approach for each report.

More detailed information on CHBRP's analysis methodology, authorizing statute, as well as all CHBRP reports and other publications, are available at chbrp.org.

Suggested citation

California Health Benefits Review Program (CHBRP). (2025). *Analysis of California Senate Bill 535 Obesity Treatment Parity Act*. Berkeley, CA.

Table of Contents

Acronyms and Abbreviations	1
Introduction	2
AB 575 Obesity Prevention Treatment Parity Act: Bill Language	2
What Is Obesity?	2
Terminology	3
Analytic Approach and Assumptions	4
Language Interpretation	4
Pharmacy Benefit Coverage	4
Policy Context	5
California Law and Regulations	5
Similar Legislation in Other States	6
Federal Policy Landscape	7
Other Federal or State Programs	8
Background on Obesity	9
Disparities in Obesity Prevalence and Treatment	13
Barriers to Accessing Obesity Treatments	14
Societal Impact of Obesity in the United States and California	15
Medical Effectiveness	16
Research Approach and Methods	16
Methodological Considerations	16
Outcomes Assessed	17
Study Findings	17
Summary of Findings	26
Benefit Coverage, Utilization, and Cost Impacts	27
Analytic Approach and Key Assumptions	27
Baseline and Postmandate Benefit Coverage	29
Baseline and Postmandate Utilization and Unit Cost	30
Baseline and Postmandate Expenditures	31
Other Considerations for Policymakers	34
Public Health Impacts	37
Estimated Public Health Outcomes	37
Impact on Disparities	38
Long-Term Impacts	39
Long-Term Utilization and Cost Impacts	39
Long-Term Public Health Impacts	39
Appendix A. Text of Bill Analyzed	A-1

Appendix B. Utilization Management..... B-1

Appendix C. Detailed Medical Effectiveness Study Findings for FDA-Approved GLP-1 AOMs C-1

Appendix D. Cost Impact Analysis: Data Sources, Caveats, and Assumptions D-1

References

California Health Benefits Review Program Committees and Staff

Acknowledgments

Lists of Tables and Figures

Table 1. Legislation Requiring Coverage for Obesity Treatment in Other States, 2025.....	6
Table 2. Prevalence of Overweight and Obesity in California’s Privately Insured Population by Age, 2023	10
Table 3. Prevalence of Diabetes, Heart Disease, and High Blood Pressure Among Overweight and Obese Adults Aged 18-64 Years in California’s Privately Insured Population, 2023	10
Table 4. FDA-Approved Drugs for Weight Management Relevant to AB 575, as of March 2025	11
Table 5. Prevalence of Overweight and Obesity Among California Adults (18-64 Years) by Key Demographic Characteristics, 2023	13
Table 6. Summary of Evidence of Medical Effectiveness of Treatments for Chronic Weight Management	26
Table 7. Impacts of AB 575 on Benefit Coverage, 2026	29
Table 8. Impacts of AB 575 on Utilization and Unit Cost, 2026	30
Table 9. AB 575 Impacts on Expenditures, 2026.....	31
Table 10. Baseline Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2026	35
Table 11. Postmandate Change in Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2026	36
Table 12. Baseline Utilization of Obesity Treatments.....	D-4
Table 13. AB 575 Impacts on Benefit Coverage, 2027	D-5
Table 14. AB 575 Impacts on Utilization and Unit Cost, 2027.....	D-6
Table 15. AB 575 Impacts on Expenditures, 2027.....	D-7
Figure 1. Health Insurance in CA and AB 575.....	2
Figure 2. Mean Percentage Weight Loss Among Adults With Overweight or Obesity, Without Diabetes	19
Figure 3. Evidence of Effectiveness of FDA-Approved AOMs for Adults	23
Figure 4. Evidence of Effectiveness of FDA-Approved AOMs for Children and Adolescents	23
Figure 5. Evidence of Effectiveness of Intensive Behavioral Therapy for Adults	24
Figure 6. Evidence of Effectiveness of Intensive Behavioral Therapy for Children and Adolescents	25
Figure 7. Expenditure Impacts of AB 575	31

Acronyms and Abbreviations

AB – Assembly Bill
ACA – Affordable Care Act
ACIP – Advisory Committee on Immunization Practices
AOM – anti-obesity medication
CA – California
CalPERS – California Public Employees' Retirement System
CDC – Centers for Disease Control and Prevention
CDI – California Department of Insurance
CHBRP – California Health Benefits Review Program
COHS – County Organized Health System
DHCS – Department of Health Care Services
DMHC – Department of Managed Health Care
EHB – essential health benefits
FDA – U.S. Food and Drug Administration
GLP-1 – glucagon-like peptide-1
HMO – Health Maintenance Organization
HRSA – Health Resources and Services Administration
IBT – intensive behavioral therapy
MHPAEA – Mental Health Parity and Addiction Equity Act
SB – Senate Bill
USPSTF – United States Preventive Services Task Force

Introduction

The Assembly Committee on Health requested that the California Health Benefits Review Program (CHBRP)⁴ conduct an evidence-based assessment of the medical, financial, and public health impacts of Assembly Bill (AB) 575, Obesity Prevention Treatment Parity Act.

AB 575 Obesity Prevention Treatment Parity Act: Bill Language

AB 575 would require coverage without prior authorization for intensive behavioral therapy (IBT) and at least one glucagon-peptide-1 (GLP-1) receptor agonist, for the treatment or prevention of obesity. In addition, the bill would prohibit coverage criteria from being more restrictive than the U.S. Food and Drug Administration (FDA)-approved indications for those treatments. See the full text of AB 575 in Appendix A.

If enacted, AB 575 would apply to the health insurance of approximately 13.6 million enrollees (35.8% of all Californians) (see Figure 1).

- **Includes:** enrollees in commercial or California Public Employees' Retirement System (CalPERS) health insurance regulated by the Department of Managed Health Care (DMHC) and the California Department of Insurance (CDI).
- **Excludes:** Medi-Cal beneficiaries enrolled in DMHC-regulated plans or county organized health system (COHS) plans.


See the following *Analytic Approach and Key Assumptions* section for additional information.

Appendix B provides an overview of prior authorization, a type of utilization management technique that is addressed in AB 575.

What Is Obesity?

Obesity is a chronic health condition characterized by an increase in the size and amount of fat cells in the body (NIH, 2022). Health care providers screen for obesity by calculating patients' body mass index (BMI), which takes into account an individual's height and weight. There are many health consequences of obesity such as an increased risk of heart disease, diabetes, respiratory issues, musculoskeletal disorders, and certain cancers, as well as reduced life expectancy (NIH, 2023). Causes of obesity are multifaceted and can include lifestyle habits, environment, stress, health conditions and certain medications, socioeconomic factors, and individual characteristics such as genetics and metabolism (CDC, 2024c).

Figure 1. Health Insurance in CA and AB 575 like



Source: California Health Benefits Review Program, 2025.

Note: CHBRP generally assumes alignment of Medi-Cal Managed Care plan benefits, with limited exceptions.¹

Key: CDI = California Department of Insurance; COHS = County Organized Health System; DHCS = Department of Health Care Services; DMHC = Department of Managed Health Care.

⁴ See [CHBRP's authorizing statute](#).

There are several methods used to treat obesity, including behavioral and lifestyle changes, anti-obesity medications (AOMs) and surgery. AB 575 focuses on one type of behavioral intervention (intensive behavioral therapy [IBT]) and one class of AOMs (GLP-1 medications). IBT is a particular form of behavioral intervention that is rigorous, structured, and involves multiple components. IBT typically lasts 1 to 2 years and provides patients with tools to support weight loss and maintenance of weight loss (e.g., food scales, pedometers). GLP-1 medications are a class of drugs that activate the body's GLP-1 receptors. This activation triggers several downstream effects, including lowering glucose (sugar) levels within the bloodstream, reducing digestion rate, and increasing the sensation of fullness for longer (Zheng et al., 2024). GLP-1 medications are indicated for type 2 diabetes and obesity, among other conditions (Collins and Costello, 2024).

Terminology

- **Anti-obesity medications (AOMs):** refers to FDA-approved drugs that are indicated for chronic weight management in people with obesity. AOMs include GLP-1 and non-GLP-1 medications.
- **GLP-1 medications:** refers to glucagon-like peptide-1 receptor agonist backbone medications, which include GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists.⁵ Note that not all GLP-1 medications are applicable to AB 575. Those that are relevant include liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound).
- **Non-GLP-1 medications:** refers to non-peptide agonists of GLP-1 receptors.

[Back to Table of Contents](#)

⁵ Gastric inhibitory polypeptide (GIP) is a hormone that directly affects the pancreas, bone, fat, gastrointestinal tract, and brain (Seino et al., 2010). GIPs contribute to the regulation of hunger sensation, among other metabolic functions (Ciardullo et al., 2024).

Analytic Approach and Assumptions

CHBRP previously analyzed similar bill language, [SB 839](#) in 2023, and [SB 1008](#) in 2024. Where applicable, this analysis builds off those previous analyses.

Language Interpretation

- Because AB 575 specifies “group and individual” plans and policies, the health insurance of Medi-Cal beneficiaries enrolled in Department of Managed Health Care (DMHC)-regulated plans would not be subject to AB 575’s requirements.⁶
- With regard to AB 575’s coverage mandate for prescription drugs, the bill language specifies that plans and policies must cover a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment or prevention of obesity. Thus, CHBRP assumes AB 575 applies to GLP-1 drugs with a U.S. Food and Drug Administration (FDA) indication for only the treatment or prevention of obesity and excludes all other indications (e.g., cardiovascular risk reduction,⁷ glycemic control). There are currently no FDA-approved GLP-1 drugs with an indication for obesity prevention. Three FDA-approved GLP-1s are indicated for chronic weight management and are included in this analysis: liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound).
- AB 575 explicitly prohibits the use of prior authorization before granting coverage for specified treatments but is silent on other utilization management techniques, such as step therapy. CHBRP assumes that the application of all utilization management techniques, with the exception of prior authorization, would be considered compliant. See Appendix B for more information on utilization management.

Pharmacy Benefit Coverage

CHBRP has assumed that plans and policies that do not have coverage for outpatient prescription drugs or brand-name outpatient prescription drugs would not be required to do so for prescriptions with an FDA indication for chronic weight management. Almost all (96.2%) commercial/California Public Employees' Retirement System (CalPERS) enrollees in plans and policies regulated by DMHC or CDI have an outpatient pharmacy benefit regulated by DMHC or CDI that covers both generic and brand-name outpatient prescription medications.⁸ Of the remaining commercial/CalPERS enrollees, 1.2% do not have a pharmacy benefit and 2.6% have a pharmacy benefit that is not regulated by DMHC or CDI. In other words, CHBRP assumes AB 575 would have no impact for plans without a regulated pharmacy benefit except for CalPERS, which is discussed in Appendix D.

[Back to Table of Contents](#)

⁶ Personal communication, Office of Legislative and Governmental Affairs, California Department of Health Care Services, November 2024.

⁷ Note that cardiovascular risk reduction is in people with known cardiovascular disease and a BMI ≥ 27 .

⁸ For more detail, please see CHBRP’s [resource](#), *Pharmacy Benefit Coverage in State-Regulated Health Insurance*.

Policy Context

Health benefit mandates may interact and align with the following state and federal mandates, programs, and policies.

California Law and Regulations

California has opted to cover anti-obesity medications (AOMs) for weight loss under its Medi-Cal program. Medi-Cal beneficiaries have coverage for GLP-1 medications with a U.S. Food and Drug Administration (FDA) indication for weight management.⁹ Quantity limits and labeler restrictions¹⁰ apply. Bariatric surgery and intensive behavioral therapy (IBT) are also covered as benefits under the Medi-Cal program.¹¹

In addition, Californians with health insurance through Federal employment have coverage for obesity treatment that include drugs with an FDA indication for weight loss and bariatric/metabolic surgeries (OPM, 2023).

Preventive Services

Existing California law requires coverage for preventive services with an “A” or “B” recommendation from the United States Preventive Services Task Force (USPSTF) without cost sharing or prior authorization for enrollees in grandfathered and nongrandfathered plans and policies.^{12,13} IBT for weight loss has a Grade “B” USPSTF recommendation (USPSTF, 2018).¹⁴

Current and Former Legislation

As mentioned above, California previously considered SB 839 (2023) and SB 1008 (2024), both of which would have required comprehensive coverage for obesity treatments, including FDA-approved drugs with an indication for chronic weight management, bariatric surgery, and intensive behavioral therapy. One primary difference between the two proposals was that SB 1008 would have required coverage of only one drug (either a GLP-1 or non-GLP-1 medication), whereas SB 839 would likely have required coverage of at least two drugs (one GLP-1 and one non-GLP-1 medication). The other major difference between the bills was related to cost sharing. SB 1008 was silent regarding cost sharing, whereas SB 839 would have required cost sharing for obesity treatments to not be different or separate from treatments for other illnesses, conditions, or disorders. SB 839 was held in the Assembly Health Committee without a hearing. SB 1008 was held in the Senate Appropriations Committee.

To date, one other legislative proposal related to obesity has been introduced in California during the current legislative session. SB 535 would require coverage for intensive behavioral therapy, bariatric surgery, and at least one FDA-approved AOM indicated for chronic weight management in patients with obesity. SB 535 is silent regarding the use of prior authorization. CHBRP is conducting a concurrent analysis of SB 535, per the request of the Senate Health Committee.

⁹ See [Medi-Cal Rx Contract Drugs List as of April 1, 2025](#).

¹⁰ Labeler restriction means the brand name (specific labeler) version of the drug must be used on the claim, rather than the generic alternative, for the claim to be paid.

¹¹ See DHCS [Essential Health Benefits](#).

¹² HSC 1367.002; INS 10112.2.

¹³ More information about the state and federal requirements to cover specified preventive services is included in CHBRP's [resource](#), *Federal Recommendations and the California and Federal Preventive Services Benefit Mandates*.

¹⁴ As of the date of publication of this analysis, the USPSTF was updating its [recommendation statement](#) related to behavioral interventions for weight loss to prevent obesity-related morbidity and mortality in adults.

Similar Legislation in Other States

Nine states have introduced legislation in the past year that would require coverage for one or more obesity treatments, including IBT and/or AOMs (Table 1). Connecticut, Iowa, and West Virginia are considering legislation that would require a committee or state agency to review the use of AOMs.¹⁵

Table 1. Legislation Requiring Coverage for Obesity Treatment in Other States, 2025.

State	Intensive Behavioral Therapy	FDA-Approved Anti-Obesity Medications	Commercial or Medicaid Mandate
Arkansas		X (a)	Both
Colorado	X	X	Commercial only
Connecticut		X	Both (b)
Florida	X	X	Medicaid only
Indiana	X	X	Both
Maine		X (a)	Both
Maryland		X	Both
Minnesota	X	X	Both
Mississippi		X	Commercial
Nevada	X		Both
New Jersey		X	Both
New Mexico		X (a)	Commercial
New York	X	X	Both
North Dakota		X	Both
Oregon	X	X	Both
Pennsylvania	X	X	Medicaid only
Texas	X	X (a)	Both (c)
Washington	X	X	Both
West Virginia		X (a)	Commercial only

Source: California Health Benefits Review Program, 2025 via LegiScan search. Data as of March 2025.¹⁶

Notes: (a) Coverage is required explicitly for GLP-1 drugs.

(b) Coverage requirement for FDA-approved anti-obesity medications is only proposed for Medicaid coverage.

(c) Coverage requirement for all treatments under Medicaid program; proposal to cover GLP-1 drugs only for commercial plans.

Key: FDA = U.S. Food and Drug Administration; GLP = glucagon-like peptide.

¹⁵ Connecticut SB01421; Iowa HF701, HSB209, SSB1138, SF552; West Virginia SB253.

¹⁶ Arkansas House Bill (HB) 1332 and HB1424; Colorado Senate Bill (SB)048; Connecticut SB01474, SB00683, and SB01000; Florida S0648 and H0713; Indiana HB1138, HB1202, and HB1552; Maine LD627 and LD480; Maryland SB876, HB1489, HB1031; Minnesota HF690 and SF1053; Mississippi HB360; Nevada AB399 and SB244; New Mexico SB193; New Jersey A1207, S2554, A1891, S2448; New York S03104, A02715, SB876, A04211, S05798; North Dakota HB1451 and HB1452; Oregon HB3517; Pennsylvania SB271; Texas SB2729, HB2677, and HB2412; Washington HB1326 and SB5353; West Virginia HB2912.

Federal Policy Landscape

Federal law authorizes the Medicaid Drug Rebate Program (MDRP), a program designed to help offset federal and state costs of most outpatient prescription drugs dispensed to Medicaid beneficiaries. The program is collaboration between the Centers for Medicare & Medicaid Services (CMS), state Medicaid agencies, and participating drug manufacturers. MDRP requires a drug manufacturer to enter into a written agreement with the Secretary of the Department of Health and Human Services that it will provide a rebate to states for a portion of the Medicaid payment for each drug. The states then share the rebate with the federal government. In return, most of the manufacturer's drugs are covered under state Medicaid programs (CMS, 2025a). Some drugs or classes of drugs may be excluded from coverage under the MDRP, including drugs used for weight loss.¹⁷ This means that states can decide whether to include coverage for obesity drugs in their Medicaid program. As of August 2024, 13 states covered GLP-1's for obesity treatment under their Medicaid programs, including California (Williams et. al., 2024).

Medicaid beneficiaries under the age of 21 years also qualify for the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefit, which provides comprehensive and preventive health care services. The EPSDT benefit includes services to prevent and reduce obesity, including BMI screening, education and counseling on nutrition and physical activity, prescription drugs that promote weight loss, and as appropriate, bariatric surgery (CMS, 2025b).

Affordable Care Act

A number of Affordable Care Act (ACA) provisions have the potential to or do interact with state benefit mandates. Below is an analysis of how AB 575 may interact with requirements of the ACA as presently exist in federal law, including the requirement for certain health insurance to cover essential health benefits (EHBs).^{18,19}

Essential health benefits

In California, nongrandfathered²⁰ individual and small-group health insurance is generally required to cover EHBs.²¹ In 2026, approximately 11% of all Californians will be enrolled in a plan or policy that must cover EHBs.²²

States may require state-regulated health insurance to offer benefits that exceed EHBs.^{23,24,25} Should California do so, the state could be required to defray the cost of additionally mandated benefits for enrollees in health plans or policies purchased through Covered California, the state's health insurance marketplace. However, state benefit mandates specifying provider types, cost sharing, or other details of existing benefit coverage would not meet the definition of state benefit mandates that could exceed EHBs.^{26,27}

¹⁷ [42 U.S. Code § 1396r-8 - Payment for covered outpatient drugs](#).

¹⁸ The ACA requires nongrandfathered small-group and individual market health insurance – including, but not limited to, qualified health plans sold in Covered California – to cover 10 specified categories of EHBs. [Policy and issue briefs](#) on EHBs and other ACA impacts are available on the CHBRP website.

¹⁹ Although many provisions of the ACA have been codified in California law, the ACA was established by the federal government, and therefore, CHBRP generally discusses the ACA as a federal law.

²⁰ A [grandfathered health plan](#) is "a group health plan that was created – or an individual health insurance policy that was purchased – on or before March 23, 2010. Plans or policies may lose their 'grandfathered' status if they make certain significant changes that reduce benefits or increase costs to consumers."

²¹ For more detail, see CHBRP's [issue brief](#), *Essential Health Benefits: An Overview of Benefits, Benchmark Plan Options, and EHBs in California*.

²² See CHBRP's [resource](#), *Sources of Health Insurance in California*.

²³ ACA Section 1311(d)(3).

²⁴ State benefit mandates enacted on or before December 31, 2011, may be included in a state's EHBs, according to the U.S. Department of Health and Human Services (HHS). [Patient Protection and Affordable Care Act; Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation](#). Final Rule. Federal Register, Vol. 78, No. 37. February 25, 2013.

²⁵ However, as laid out in the Final Rule on EHBs U.S. Department of Health and Human Services (HHS) released in February 2013, state benefit mandates enacted on or before December 31, 2011, would be included in the state's EHBs, and there would be no requirement that the state defray the costs of those state-mandated benefits. For state benefit mandates enacted after December 31, 2011, that are identified as exceeding EHBs, the state would be required to defray the cost.

²⁶ Essential Health Benefits. Final Rule. A state's health insurance marketplace would be responsible for determining when a state benefit mandate exceeds EHBs, and qualified health plan issuers would be responsible for calculating the cost that must be defrayed. [Patient Protection and Affordable Care Act; Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation](#). Final Rule. Federal Register, Vol. 78, No. 37. February 25, 2013.

²⁷ Both Massachusetts and Utah currently pay defrayment costs for exceeding EHBs. For more information about defrayal, refer to CHBRP's [issue brief](#) *Essential Health Benefits: Exceeding EHBs and the Defrayal Requirement*.

As the drugs and behavioral therapy that are the focus of this analysis are regularly covered under the EHB benchmark plan, it seems unlikely that AB 575 would exceed the definition of EHBs in California.

Other Federal or State Programs

The Centers for Disease Control and Prevention (CDC) currently funds 16 land grant universities to run the High Obesity Program, a 5-year cooperative agreement intended to reduce health disparities in mostly rural counties with adult obesity rates higher than 40%. The current program began in 2023 and focuses on increasing food and nutrition security, increasing physical activity through community design, and early care and education settings. No universities in the state of California were awarded funding under the current High Obesity Program (CDC, 2025).

CDC also currently funds 17 states to conduct the current 5-year State Physical Activity and Nutrition program, which aims to make healthy eating and active living more accessible through the implementation of evidence-based strategies to promote food service and nutrition guidelines, for safe and accessible physical activity, for continuity of care in breastfeeding support, and early care and education settings (CDC, 2024d). The California Department of Public Health was a recipient of State Physical Activity and Nutrition program funding for fiscal year 2024.

[Back to Table of Contents](#)

Background on Obesity

AB 575 would require an individual or group health care service plan contract or health insurance policy that provides coverage for outpatient prescription drug benefits, to include coverage for at least one glucagon-like peptide-1 (GLP-1) U.S. Food and Drug Administration (FDA)-approved for weight loss, and IBT for the treatment of obesity without prior authorization. This background section provides information related to obesity to provide context for the consideration of the *Medical Effectiveness*; *Benefit Coverage*, *Utilization*, and *Cost Impacts*; and *Public Health Impacts* sections.

Obesity is a chronic health condition characterized by an increase in the size and amount of fat cells in the body (NIH, 2022). Health care providers screen for obesity by calculating patients' body mass index (BMI), which takes into account an individual's height and weight. Adults with a BMI of 25 to <30 are categorized as overweight and those with a BMI of 30 or higher are categorized as obese. The adult obese category can be further delineated into three categories (CDC, 2024a):

- Class 1: BMI of 30 to <35
- Class 2: BMI of 35 to <40
- Class 3: BMI of 40 or higher

In children, BMI categories to define overweight and obesity are defined based on sex-specific BMI-for-age percentiles. The BMI categories for children and teens aged 2-19 years are provided below (CDC, 2024b):

- Underweight: BMI in <5th percentile
- Healthy Weight: BMI in 5th-<85th percentile
- Overweight: BMI in 85th percentile – <95th percentile
- Obesity: BMI in 95th percentile or greater
- Severe Obesity: BMI in 120% of the 95th percentile or greater, or 35 kg/m² or greater

Table 2 describes the prevalence of overweight and obesity in the privately insured population in California by age. Obesity treatments are recommended for individuals with obesity, as well as for some who are overweight (i.e., individuals with BMI ≥27 to <30) and have comorbidities such as cardiovascular disease, type 2 diabetes, and hypertension (Jensen et al., 2014). Data in Table 2 show patterns in overweight and obesity by age, with rates increasing with age. Overall, it is estimated that 10.0% of adolescents aged 12 to 17 years and 27.5% of adults aged 18 to 64 years with private health insurance in California have BMIs that would categorize them as having obesity.

Table 2. Prevalence of Overweight and Obesity in California's Privately Insured Population by Age, 2023

Age, Years	Overweight, % (a) (BMI 25.0 to <30)	Obese, % (BMI ≥30)
12-17 (b)	15.3	10.0
18-24	23.7	16.4
25-39	30.3	24.9
40-64	34.4	31.9
18-64 (c)	31.6	27.5

Source: California Health Benefits Review Program, 2025, analysis of the 2023 California Health Interview Survey Data.

Analysis was limited to respondents with employment-based and privately purchased health insurance.

Note: (a) A proportion of those who have BMIs between 27 and 29.9 would also be eligible for obesity treatments if they have additional comorbidities. This has been estimated to be 7% of the privately insured non-elderly adult population (McGough et. al., 2024).

(b) Overweight for children under age 18 years is defined as having a BMI between the 85th and 95th percentile, whereas obesity is defined as having a BMI in the 95th percentile or above (CDC, 2024b). Estimates for teens (aged 12-17 years) are presented because the data source did not include information on obesity rates for children aged 0 to 12 years.

(c) In addition, rates for adults >65 years are not presented because the vast majority of that population is enrolled in Medicare and thus not enrolled in health insurance subject to AB 575.

Key: BMI = body mass index.

In addition, it is estimated that 7% of adult Californians with health insurance subject to AB 575 would also be medically eligible for treatment due to having BMIs ≥27 and <30 and the presence of comorbidities (McGough et. al., 2024). This translates into an additional 200,000 Californians eligible for obesity treatments enrolled in health insurance subject to AB 575, for a total of 3.1 million (Table 3). For example, among those who have BMIs between 27 and 30, 8.4% have ever been diagnosed with diabetes, 3.8% have heart disease and 15.4% have ever been diagnosed with high blood pressure.

Table 3. Prevalence of Diabetes, Heart Disease, and High Blood Pressure Among Overweight and Obese Adults Aged 18-64 Years in California's Privately Insured Population, 2023

	Overweight, %* (BMI 27 to <30)	Obese, % (BMI ≥30)
Ever diagnosed with diabetes	8.4	14.1
Has heart disease	3.8	3.6
Blood pressure not under control in the past year	15.4	11.2

Source: California Health Benefits Review Program, 2025, analysis of the 2023 California Health Interview Survey Data.

Analysis is limited to respondents with employment-based and privately purchased health insurance.

Note: * A proportion of those who have BMIs between 27 and 29.9 would also be eligible for obesity treatments if they have additional comorbidities. This has been estimated to be 7% of the total, non-elderly adult population with private insurance (McGough et. al., 2024).

Key: BMI = body mass index.

Treatments for Obesity Weight Management

There are two types of treatments for obesity that are relevant to AB 575: GLP-1 drugs approved by the FDA with an indication for chronic weight management and intensive behavioral therapy (IBT) (Cornier, 2022). Selection of treatments should take into consideration patient preference, individual patient characteristics, and the implications for patients with

multiple comorbidities. A description and summary of clinical practice guidelines for each type of treatment is described in more detail below.

Drugs With FDA Indication for Chronic Weight Management

There are two main types of drugs approved by the FDA with an indication for chronic weight management – known as AOMs: glucagon-like peptide 1 (GLP-1) receptor agonists and non-GLP-1 medications. Non-GLP-1 AOMs were developed and introduced to the market primarily for the treatment of obesity as early as the 1950s. One such medication, phentermine, was approved by the FDA in 1959 and remains in use today. In contrast, GLP-1 receptor agonists were first discovered in 1984 and initially approved by the FDA in 2005 for the treatment of type 2 diabetes. It wasn't until 2014 that the FDA approved Saxenda (liraglutide) as the first GLP-1 specifically indicated for weight management. As of March 2025, there are eight different FDA-approved GLP-1 medications of which three are FDA-approved specifically for the treatment of obesity. In addition there are four non-GLP-1s with FDA indications for chronic weight management. Table 4 describes the three drugs relevant to AB 575 (i.e. GLP-1s with FDA indications for chronic weight management). Other GLP-1 medications that are FDA-approved for other conditions are not relevant to AB 575 and are excluded from the table below. The drug name, brand name, year of FDA approval, mode of administration, and population for which the drug is approved are also presented in the table.

Table 4. FDA-Approved Drugs for Weight Management Relevant to AB 575, as of March 2025

Drug (Brand Name)	FDA Approval Year	Frequency/Mode of Administration	Population Approved/ Indicated For
GLP-1 FDA-approved for chronic weight management			
Liraglutide (Saxenda)	2014 adults; 2020 aged 12+ years	Daily, subcutaneous	Adults with BMI of ≥ 30 kg/m ² or ≥ 27 kg/m ² with comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). 12+ years with body weight above 60 kg and an initial BMI corresponding to 30 kg/m ² for adults by international cut-offs.
Semaglutide (Wegovy)	2021 adults; 2023 aged 12+	Weekly, subcutaneous, gradually increase dose every 4 weeks.	Adults with BMI ≥ 30 kg/m ² or ≥ 27 kg/m ² in the presence of comorbid condition. 12+ years with BMI at the 95th percentile or greater standardized for age and sex.
Tirzepatide (Zepbound)*	2023	Weekly, subcutaneous	Adults with BMI ≥ 30 kg/m ² or ≥ 27 kg/m ² with comorbid condition.

Source: California Health Benefits Review Program, 2025; FDA, 2025a.

Note: * Tirzepatide (Zepbound) is a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1.

Key: BMI = body mass index; FDA = U.S. Food and Drug Administration; GLP-1 = glucagon-like peptide-1.

GLP-1s work by activating GLP-1 receptors in the body, which slows down how quickly food moves through the body and increases the sensation of fullness for longer (Ard et al., 2021). Non-GLP-1 therapies involve many different mechanisms of action such as reduction of absorption of fat (Orlistat), reduction in the deposition of fat (phentermine), and suppression of appetite (bupropion/naltrexone, naltrexone) (Aaseth et al., 2021; Verrotti et al., 2011).

A recent poll found that 12% of U.S. adults have used a GLP-1 medication, with 6% currently taking one (Montero et. al., 2024). Among users, 39% took them for chronic conditions such as diabetes or heart disease, whereas 38% used them primarily for weight loss, and 23% used them to both lose weight and to treat a chronic condition (Montero et. al., 2024). Specifically, GLP-1 usage was 43% among those with diabetes, 26% among those with heart disease, and 22% among individuals classified as overweight or obese (Montero et. al., 2024).

Distribution of GLP-1s and the role of compounding pharmacies

Compounding pharmacies are a specialized type of pharmacy that combines, mixes, or alters ingredients of a drug to create a medication that is tailored to specific patient needs (FDA, 2024). Compounding pharmacies are not FDA approved, but they are permitted to replicate commercially available drugs when the active ingredients are listed on the FDA's drug shortage list (NCSL, 2024). Three GLP-1s FDA-approved to treat obesity (liraglutide, semaglutide, and tirzepatide) were previously on the FDA's drug shortage list, but as of March 2025, these shortages have been deemed resolved by the FDA (FDA, 2025b). As a result, compounding pharmacies have been asked to stop producing and selling these drugs (FDA, 2025b). Therefore, this analysis will assume that enrollees are no longer getting these drugs through compounding pharmacies.

Clinical practice guidelines for adults

In 2018, the United States Preventive Services Task Force (USPSTF) recommended that clinicians promote behavioral interventions as the primary intervention for weight management in adults (USPSTF, 2018). Multiple additional studies of weight management drugs have been published since the USPSTF systematic review was published in 2018 recommending behavioral interventions as the first line of therapy. The 2022 American Gastroenterological Association *Clinical Practice Guidelines on Pharmacological Interventions for Adults With Obesity* recommends the use of pharmacotherapy in addition to lifestyle modifications in adults with overweight or obesity who have inadequate response to lifestyle interventions (Grunvald et al., 2022). In addition this guideline recommends that semaglutide 2.4 mg be prioritized over other AOMs.

Guidance on weight management drugs for children and adolescents

In 2023, the American Academy of Pediatrics (AAP) issued a clinical practice guideline regarding weight management drugs for children and adolescents with obesity that states "Pediatricians and other pediatric health care providers should offer adolescents 12 years and older with obesity (BMI $\geq$ 95th percentile) weight loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment" (Hampl et al., 2023).

Intensive Behavioral Therapy

The USPSTF defines intensive behavioral therapy (IBT) for obesity as a particular form of intensive, multicomponent behavioral intervention that typically lasts for 1 to 2 years, encompasses 12 or more sessions during the first year, and provides patients with tools to support weight loss and maintenance of weight loss (e.g., food scales, pedometers) (USPSTF, 2018). Many IBTs are modeled after the Diabetes Prevention Program (USPSTF, 2018). This program includes weekly group meetings led by a trained lifestyle coach for 6 months, followed by 6 months of meeting once or twice a month. The Diabetes Prevention Program curriculum is offered through a variety of organizations across the United States that are part of the Centers for Disease Control and Prevention's (CDC's) national registry of recognized organizations (CDC, 2023b).

Guidance on IBT for adults

In 2018, the USPSTF recommended that "clinicians offer or refer adults with a body mass index of 30 or higher to intensive, multicomponent behavioral interventions." The USPSTF (2018) concluded that effective behavioral intervention for weight loss has the following characteristics:

- Designed to help participants achieve or maintain a $\geq$ 5% weight loss through a combination of dietary changes and increased physical activity;
- Lasted for 1 to 2 years, and, in the majority of cases, had $\geq$ 12 sessions in the first year;
- Focused on problem solving to identify barriers to weight loss, self-monitoring of weight, peer support, and relapse prevention; and
- Provided tools to support weight loss or weight loss maintenance (e.g., pedometers, food scales, or exercise videos).

Guidance on IBT for children and adolescents

In 2023, the AAP issued a clinical practice guideline regarding IBT²⁸ for children and adolescents with obesity that states “Pediatricians and other pediatric health care providers should provide or refer children 6 years and older and may provide or refer children 2 through 5 years of age with overweight (BMI $\geq$ 85th percentile to $<$ 95th percentile) and obesity (BMI $\geq$ 95th percentile) to health behavior and lifestyle treatment” (Hampl et al., 2023).

Disparities²⁹ in Obesity Prevalence and Treatment

Disparities are noticeable and preventable or modifiable differences between groups of people. Health insurance benefit mandates or related legislation may impact disparities. Where intersections between health insurance benefit mandates and social drivers or systemic factors exist, CHBRP describes relevant literature. CHBRP found literature identifying disparities by race/ethnicity, income, and geography.

Table 5 demonstrates patterns in overweight and obesity by key demographics among California adults. Obesity rates are lowest among those with the highest incomes and educational attainment. Rates of obesity vary in California by race and ethnicity with Asian adults reporting the lowest rates of obesity (11.0%) followed by White adults (25.5%), and American Indian/Alaska Native adults (42%), with Black adults (42.7%), and Latino adults (43.3%) all reporting the highest rates. In addition, adults residing in urban locations reported lower rates of obesity compared to adults residing in rural locations. Finally, rates of obesity did not vary significantly by gender or sexual orientation.

Table 5. Prevalence of Overweight and Obesity Among California Adults (18-64 Years) by Key Demographic Characteristics, 2023

Demographic Characteristic	Overweight, % (a) (BMI 25.0 - <30)	Obese, % (BMI $\geq$ 30)
Race/ethnicity		
American Indian/Alaska Native	35.1	25.3
Asian	28.9	11.0
Black	31.4	42.7
Latino	33.0	43.3
White	32.2	25.5
Gender³⁰		
Female	25.6	27.3
Male	37.6	27.8
Transgender or gender nonconforming	21.8	20.1
Sexual orientation		
Straight/heterosexual	32.4	27.7
Gay, lesbian, bisexual, asexual	25.9	27.6

²⁸ The American Academy of Pediatrics uses the terminology “intensive health behavior treatment.”

²⁹ Several competing definitions of “health disparities” exist. CHBRP relies on the following definition: Health disparity is defined as the differences, whether unjust or not, in health status or outcomes within a population. (Wyatt et al., 2016).

³⁰ CHBRP uses the NIH distinction between “sex” and “gender”: “‘Sex’ refers to biological differences between females and males, including chromosomes, sex organs, and endogenous hormonal profiles. ‘Gender’ refers to socially constructed and enacted roles and behaviors which occur in a historical and cultural context and vary across societies and over time.” (NIH, 2019).

Demographic Characteristic	Overweight, % (a) (BMI 25.0 - <30)	Obese, % (BMI ≥30)
Federal poverty level		
0%-99%	30.1	31.6
100%-199%	32.8	35.0
200%-299%	29.9	35.5
300%+	31.9	25.5
Location of residence		
Urban	31.8	27.0
Rural	31.1	33.4
Education		
<High school	33.3	38.5
High school graduate	28.4	34.5
Some college/vocational school	31.7	35.4
College graduate	32.6	21.8

Source: California Health Benefits Review Program, 2025, analysis of 2023 California Health Interview Survey Data.

Note: (a) A proportion of those who have BMIs between 27 and 29.9 would also be eligible for obesity treatments if they have additional comorbidities. This has been estimated to be 7% of the privately insured non-elderly adult population (McGough et al., 2024).

(b) Overweight for children under age 18 years is defined as having a BMI between the 85th and 95th percentile, whereas obesity is defined as having a BMI in the 95th percentile or above (NIH, 2022).

Key: BMI = body mass index.

Barriers to Accessing Obesity Treatments

It is estimated that only 10% of those with obesity seek help from a professional to lose weight, with approximately 6.4% consulting a non-physician health professional (dietician, personal trainer, etc.) and 3.6% consulting a physician (Stokes et al., 2018). While not everyone with obesity is diagnosed and attempts to seek treatments, among those who do, there are still many factors that serve as barriers to accessing treatments such as:

- **Stigma:** People with obesity often face stigma and discrimination, which make them less likely to engage with the health care system. In addition, physicians may negatively stereotype patients with higher BMIs resulting in a lower likelihood of recommending treatments (Washington et al., 2023). Furthermore, concerns about the unintentional stigmatization of patients and maintaining the patient–provider relationship may further contribute to reluctance among providers to address obesity as an issue (Mekonnen et al., 2024).
- **Racism and discrimination:** People of color have higher rates of obesity. This is in part because they are more likely to live in neighborhoods with obesogenic food environments (Washington et al., 2023). Black and Latino adults are also more likely to develop an obesity-related disease such as high blood pressure, heart attack, and stroke (Washington et al., 2023). In addition to there being disparities in obesity rates by race and ethnicity, there are also disparities in access to anti-obesity treatments and outcomes. Specifically, it was found that Black and Hispanic adults with obesity were more likely to have financial barriers to accessing GLP-1s and were less likely to receive prescriptions compared to White adults (Lu et al., 2022). Furthermore, people of color who have obesity are less likely to be assessed for and diagnosed with obesity and offered treatments for obesity (Gasoyan et al., 2024; Washington et al., 2023).
- **Location:** Rates of obesity are higher among rural adults (31.0%) compared to urban adults (25.2%). In addition, the concentration of obesity medicine specialists in more urban and suburban areas makes it more difficult for adults diagnosed with obesity in rural areas to access care. People living in rural areas are more likely to face challenges in finding a health care provider that specializes in obesity medicine and are likely to live further away from major

surgery centers. It is estimated that the travel time to an obesity medicine specialist is almost five times as long for adults in rural areas compared to adults in urban areas (43 vs. 9 minutes) (Washington et al., 2023).

- **Comorbidity factors:** A recent study suggests that most patients seek treatment for obesity-related comorbidities such as type 2 diabetes and cardiovascular disease rather than for obesity itself, leading providers to prioritize these conditions instead (Aboueid et al., 2018; Hersch et al., 2021).
- **Expense:** The high cost of some obesity treatments can make them inaccessible for patients with lower incomes (Levi et al., 2023). As shown in Table 5, those in the highest income group (>300% FPL) have much lower rates of obesity than those in the lower income groups. This is in part because people with lower incomes are more likely to find it challenging to address lifestyle factors contributing to obesity such as a lack of time and money to dedicate to healthy meal preparation and exercise, a higher likelihood of living in a built environment that is not conducive to eating healthy and exercising, and a higher likelihood of experiencing stress (Washington et al., 2023). More than half (54%) of those who have taken GLP-1 drugs found them difficult to afford, even with insurance covering part of the expense (Montero et al., 2024).

Societal Impact of Obesity in the United States and California

The treatment of obesity-related diseases places a large economic burden on society. In a report by the Milken Institute, researchers estimated that the total economic costs attributed to overweight and obesity in the United States exceeded \$1.72 trillion — comprising \$480.7 billion in direct health care costs due to diseases caused by overweight and obesity, and an additional \$1.24 trillion in indirect costs due to lost productivity in 2016 (Waters and Graf, 2018). Translated into 2025 dollars,³¹ the total direct and indirect costs related to overweight and obesity equate to \$2.3 trillion per year in the United States.

When evaluating direct medical care costs attributed to obesity in the United States, Cawley et al. (2021a) found that the annual average medical expenditures for adults with obesity (\$5,010) were approximately twice as high as those incurred by adults with normal weight (\$2,504). In addition, obesity increased costs within every level of medical care (i.e., inpatient, outpatient, and medications). Furthermore, Cawley et al. (2021a) found that as the class of obesity increased (Class 1, 2, and 3), so did the amount of annual medical expenditures. Relative to those with normal weight (BMI 18.5 to ≤25), additional medical expenditures increased by 68.4% (or \$1,713) among those with class 1 obesity, by 120% (or \$3,005) among those with class 2 obesity, and by 233.6% (or \$5,850) among those with class 3 obesity, respectively.

Within California, Cawley et al. (2021a) estimated the total annual medical expenditure related to adult obesity (i.e., BMI ≥30). In 2016, the total annual medical care expenditures (i.e., direct costs comprised of public and private health insurance expenditures as well as out-of-pocket costs) due to obesity in California was equal to \$5.3 billion (Cawley et al., 2021a). Translated into 2025 dollars, the total medical expenditures attributed to obesity in California is equal to \$7.1 billion.

[Back to Table of Contents](#)

³¹ Translated into 2025 dollars using <https://www.usinflationcalculator.com/>.

Medical Effectiveness

As discussed in the *Policy Context* section, AB 575 would mandate coverage of intensive behavioral therapy (IBT) and at least one U.S. Food and Drug Administration (FDA)-approved glucagon-like peptide-1 (GLP-1) anti-obesity medication (AOM) indicated for chronic weight management in patients with obesity. In addition, the bill would prohibit coverage criteria from being more restrictive than the FDA-approved indications for those treatments. Additional information on obesity and treatments is included in the *Background on Obesity* section. The medical effectiveness review summarizes findings from evidence³² on IBT, and FDA-approved GLP-1 AOMs indicated for chronic weight management in patients with obesity.

Research Approach and Methods

The search was limited to studies published from 2024 to the present because CHBRP had previously conducted thorough literature searches on these topics in 2023 for SB 839 and in 2024 for SB 1008.³³ Study findings included in the CHBRP publications for SB 839 and SB 1008 are included in this report to provide a comprehensive review of the literature on these topics and to support the new evidence presented.

A total of 20 studies were included in the medical effectiveness review for this report. The other articles were eliminated because they did not focus on the treatments for which AB 575 would require coverage, assessed medications that are not FDA-approved for chronic weight management, were of poor quality, did not report findings from clinical research studies, or did not report weight-related outcomes. A more thorough description of the methods used to conduct the medical effectiveness review and the process used to grade the evidence for each outcome measure is presented in CHBRP's [Medical Effectiveness Analysis and Research Approach](#) document.

The conclusions below are based on the best available evidence from peer-reviewed and grey literature.³⁴ Unpublished studies are not reviewed because the results of such studies, if they exist, cannot be obtained within the 60-day timeframe for CHBRP reports.

Key Questions

1. In adults and adolescents with obesity, what is the effect of IBT and FDA-approved GLP-1 AOMs on a reduction in the incidence of adult and adolescent obesity compared with no intervention or in conjunction with another treatment?
2. What is the effect of IBT and FDA-approved GLP-1 AOMs on additional associated health outcomes in adults and adolescents with obesity compared with no intervention or in conjunction with another treatment?
3. What are the harms of IBT and FDA-approved GLP-1 AOMs for adults and adolescents with obesity compared with no intervention or in conjunction with another treatment?

Methodological Considerations

CHBRP's literature review of treatments for obesity focused on the IBT and FDA-approved GLP-1 AOMs indicated for chronic weight management. CHBRP's review of literature on behavioral health interventions for weight management was limited to IBT because AB 575 only requires coverage for IBT and does not address coverage for less intensive behavioral interventions for weight management. CHBRP limited its review of literature on GLP-1 AOMs to medications

³² Much of the discussion in this section is focused on reviews of available literature. However, as noted in the section on Implementing the Hierarchy of Evidence in the Medical Effectiveness Analysis and Research Approach document, in the absence of fully applicable to the analysis peer-reviewed literature on well-designed randomized controlled trials (RCTs), CHBRP's hierarchy of evidence allows for the inclusion of other evidence.

³³ Studies of the effects of IBT and FDA-approved AOMs indicated for chronic weight management in patients with obesity were identified through searches of Embase, PsycINFO, Ovid MEDLINE, Cochrane Library, PubMed, and Scopus. The search was limited to abstracts of studies published in English.

³⁴ Grey literature consists of material that is not published commercially or indexed systematically in bibliographic databases. See CHBRP's [website](#) for more information.

that the FDA has approved for weight management because AB 575 would only require health plans and policies to cover GLP-1 medications that are specifically FDA-approved for chronic weight management.

Outcomes Assessed

Primary outcomes assessed included: change in body weight; percent weight loss; weight reduction of 5%,³⁵ 10%, 15%, or 20%; change in body mass index (BMI); and change in waist circumference. Health outcomes associated with obesity included: impact on quality of life and physical functioning; diabetes risk; changes in hemoglobin (A1c); and changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP). CHBRP also reviewed literature on harms of FDA-approved AOMs.

Study Findings

This following section summarizes CHBRP's findings regarding the strength of evidence for the effectiveness of IBT and FDA-approved GLP-1 AOMs indicated for chronic weight management. Each section is accompanied by a corresponding figure. The title of the figure indicates the test, treatment, or service for which evidence is summarized. The statement in the box above the figure presents CHBRP's conclusion regarding the strength of evidence about the effect of a particular test, treatment, or service based on a specific relevant outcome and the number of studies on which CHBRP's conclusion is based. Definitions of CHBRP's grading scale terms are included in the box below.

The following terms are used to characterize the body of evidence regarding an outcome:

Very strong evidence indicates that there are multiple studies of a treatment and the large majority of studies are of high quality and consistently find that the treatment is either effective or not effective. Conclusions are unlikely to be altered by additional evidence.

Strong evidence indicates that the majority of the studies reviewed are consistent in their findings that treatment is either effective or not effective. Conclusions could be altered with additional strong evidence.

Some evidence indicates that a small number of studies have limited generalizability to the population of interest and/or the studies have a serious methodological concern in research design or implementation. Conclusions could be altered with additional evidence.

Conflicting evidence indicates that a similar number of studies of equal quality suggest the treatment is effective as suggest the treatment is not effective.

Not enough research indicates that there are no studies of the treatment or the available studies are not of high quality, meaning there is not enough evidence available to know whether or not a treatment is effective. It does not indicate that a treatment is not effective.

Effect of FDA-Approved AOMs on Weight Management Outcomes

Additional details about the evidence presented in this *Medical Effectiveness* section are available in Appendix C. In some cases, the FDA-approved AOMs were compared to placebo. In other cases, the FDA-approved AOMs were provided in conjunction with lifestyle intervention or another intervention and were compared with placebo plus lifestyle intervention or another intervention.

³⁵ The U.S. Food and Drug Administration considers a weight loss of 5% as clinically important (LeBlanc et al., 2018).

Effect of GLP-1 AOMs

Liraglutide 3.0 mg (Saxenda)

Effectiveness of liraglutide on weight management outcomes in adults: One randomized controlled trial (RCT) of adults with overweight or obesity and symptomatic knee osteoarthritis found that liraglutide led to significantly greater reductions in body weight and waist circumference compared to placebo, with significantly higher proportions of liraglutide participants achieving $\geq 5\%$ weight loss (Gudbergson et al., 2021).

Two studies of adults with overweight or obesity reported that liraglutide resulted in significantly greater percent body weight loss and higher proportions of participants achieving $\geq 5\%$ and $\geq 10\%$ weight loss compared to control treatments (Atlas et al., 2022; Shi et al., 2024).

Effectiveness of liraglutide on weight management outcomes in children and adolescents: A meta-analysis of two RCTs reported no statistically significant differences in body weight loss or BMI reduction between liraglutide and placebo among participants aged 5 to 18 years with obesity (Cornejo-Estrada et al., 2023).

Semaglutide 2.4 mg (Wegovy)

Effectiveness of semaglutide on weight management outcomes in adults: Two RCTs found significantly greater reductions in percent body weight with semaglutide compared to control treatments among adults with overweight or obesity (Shi et al., 2024) and adults with obesity-related heart failure and type 2 diabetes (Kosiborod et al., 2024).

Three RCTs reported significantly greater reductions in body weight and waist circumference with semaglutide compared to control treatments among adults with overweight or obesity and type 2 diabetes (Davies et al., 2021), pre-existing cardiovascular disease but no diabetes (Lincoff et al., 2023), or prediabetes (McGowan et al., 2024).

One systematic review and meta-analysis found significantly greater reductions in percent body weight, absolute body weight, BMI, and waist circumference with semaglutide compared to placebo in adults with overweight or obesity without diabetes (Qin et al., 2024).

Significantly higher proportions of semaglutide participants achieved $\geq 5\%$ and $\geq 10\%$ weight loss (Davies et al., 2021; McGowan et al., 2024; Qin et al., 2024; Shi et al., 2024), $\geq 15\%$ weight loss (Davies et al., 2021; McGowan et al., 2024; Qin et al., 2024), and $\geq 20\%$ weight loss (McGowan et al., 2024; Qin et al., 2024) compared to control group participants.

Effectiveness of semaglutide on weight management outcomes in children and adolescents: One RCT reported significantly greater BMI reduction and a significantly higher likelihood of achieving $\geq 5\%$ weight loss with semaglutide compared to placebo among adolescents aged 12 to 18 years with obesity or with overweight and at least one weight-related coexisting condition (Weghuber et al., 2022).

A post hoc analysis of the aforementioned Weghuber et al. (2022) trial found that semaglutide participants were significantly more likely to be reclassified to a normal-weight or overweight BMI category and had significantly higher odds of achieving an improvement of at least one BMI category (Kelly et al., 2023).

Tirzepatide (Zepbound)

Effectiveness of tirzepatide on weight management outcomes in adults: One RCT and one systematic review/meta-analysis reported that tirzepatide (5 mg, 10 mg, and 15 mg) led to significantly greater reductions in percent body weight (Jastreboff et al., 2022; Liu et al., 2024) as well as BMI and waist circumference (Liu et al., 2024) than control treatments.


Significantly greater proportions of participants achieved $\geq 5\%$ weight loss for all tirzepatide dosages, and significantly more participants in the 10 mg and 15 mg groups achieved $\geq 20\%$ weight loss (Jastreboff et al., 2022). Significantly higher proportions of tirzepatide participants achieved $\geq 5\%$, $\geq 10\%$, $\geq 15\%$, $\geq 20\%$, and $\geq 25\%$ weight loss versus placebo (Liu et al., 2024).

Effectiveness of tirzepatide on weight management outcomes in children and adolescents: Tirzepatide is not approved for use in children and adolescents.

Drug-to-Drug Comparison of FDA-Approved AOMs

In a network meta-analysis of five RCTs³⁶ (N = 11,414) involving adults with overweight or obesity without diabetes, Alkhezi et al. (2023) found that tirzepatide 10 mg and 15 mg, semaglutide 2.4 mg, and liraglutide 3.0 mg were associated with significantly more weight loss and significantly greater proportions of participants with ≥5%, ≥10%, ≥15%, and ≥20% weight loss than placebo (except liraglutide for the ≥15% and ≥20% comparisons). Both doses of tirzepatide resulted in significantly greater weight loss than semaglutide and liraglutide, whereas semaglutide yielded significantly greater weight loss than liraglutide. Tirzepatide 10 mg and 15 mg and semaglutide had significantly higher odds of achieving ≥5% to 20% weight loss than liraglutide. See Figure 2 below.

Figure 2. Mean Percentage Weight Loss Among Adults With Overweight or Obesity, Without Diabetes



Source: California Health Benefits Review Program, 2025; Alkhezi et al., 2023.
Key: Bold values indicate comparisons with significant differences.

Impact of FDA-Approved AOMs on Other Health Outcomes

Quality of life and physical functioning outcomes for GLP-1s

Liraglutide 3.0 mg (Saxenda)

Liraglutide was associated with greater improvements in health status (Atlas et al., 2022), functional outcomes (Jobanputra et al., 2023), and health-related quality of life (Shi et al., 2024) compared to control treatments among adults with overweight or obesity. One study found no significant difference in knee pain relief (Gudbergensen et al., 2021), and one study found no significant difference in depression symptom scores (Shi et al., 2024) between liraglutide and control treatments.

³⁶ One RCT employed lifestyle counseling in addition to both the GLP-1 and placebo treatments, three RCTs employed lifestyle modification, and one RCT employed IBT plus a low-calorie diet.

Semaglutide 2.4 mg (Wegovy)

Among adults with overweight or obesity, semaglutide was associated with greater improvements in functional outcomes (Davies et al., 2021; Jobanputra et al., 2023; Kosiborod et al., 2024), health status (Lincoff et al., 2023), and health-related quality of life (Qin et al., 2024; Shi et al., 2024) compared to control treatments.

Among adolescents with overweight or obesity, semaglutide was associated with significant improvements in weight-related quality of life overall and in the physical comfort domain of the Impact of Weight on Quality of Life (IWQOL) – Kids questionnaire. There were no significant differences between semaglutide and the control treatment in regard to the body esteem, social life, or family relations domains of the questionnaire (Weghuber et al., 2022).

Tirzepatide (Zepbound)

Tirzepatide was associated with significantly greater improvements in physical functioning (Jastreboff et al., 2022; Liu et al., 2024) and quality of life (Liu et al., 2024) compared to control treatments among adults with overweight or obesity.

Type 2 diabetes risk assessment outcomes for GLP-1s

Assessing fasting plasma glucose (FPG) levels (which provide a snapshot of blood sugar at a specific point in time), blood glucose levels, fasting serum insulin levels (which measures insulin levels in the bloodstream), and dyslipidemia (an abnormal distribution of lipids within the bloodstream), aid in the diagnosis of diabetes (Nichols et al., 2008; Schofield et al., 2016).

Liraglutide 3.0 mg (Saxenda)

Among adults with overweight or obesity, six trials indicated greater improvements in blood glucose with liraglutide compared to control treatments. Only three of five trials identified benefits to low-density lipoprotein cholesterol with liraglutide (Atlas et al., 2022).

Liraglutide did not increase hypoglycemic episodes compared to placebo among participants aged 5 to 18 years with obesity (Cornejo-Estrada et al., 2023).

Semaglutide 2.4 mg (Wegovy)

Among adults with overweight or obesity, semaglutide was associated with greater improvements in FPG levels, fasting serum insulin levels, and lipid profile measures³⁷ compared to control treatments (Davies et al., 2021; Lincoff et al., 2023; McGowan et al., 2024; Qin et al., 2024; Wadden et al., 2021) and greater improvements in cardiometabolic factors (Wilkinson et al., 2023). A significantly greater proportion of participants with obesity and prediabetes returned to normoglycemia at week 52 with semaglutide control to the control treatment (McGowan et al., 2024).

Tirzepatide (Zepbound)

Tirzepatide for adults with overweight or obesity was associated with significant improvements in fasting insulin and lipid levels, and higher likelihood of returning to normoglycemia (Jastreboff et al., 2022).

Hemoglobin A1c outcomes for GLP-1s

The hemoglobin A1c (also known as glycated hemoglobin, glycosylated hemoglobin, HbA1c, or A1c) test measures a person's average level of blood sugar (glucose) over the past 90 days. Higher HbA1c levels suggest poor blood sugar control and increased risk of diabetes-related complications, which contributes to obesity (Eyth and Naik, 2023).

³⁷ Lipid profile comprises total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, free fatty acids, and triglycerides.

Liraglutide 3.0 mg (Saxenda)

Liraglutide was associated with greater improvements in HbA1c compared to control treatments among adults with overweight or obesity (Alkhezi et al., 2023; Atlas et al., 2022).

Semaglutide 2.4 mg (Wegovy)

Among adults with overweight or obesity, semaglutide was associated with significantly greater reductions in HbA1c (Alkhezi et al., 2023; Davies et al., 2021; McGowan et al., 2024; Qin et al., 2024) and significantly greater improvements in glycated hemoglobin (Lincoff et al., 2023; Wadden et al., 2021) compared to control treatments.

Tirzepatide (Zepbound)

Tirzepatide was associated with significant reductions in HbA1c compared to control treatments among adults with overweight or obesity (Alkhezi et al., 2023; Liu et al., 2024).

Blood pressure outcomes for GLP-1s

Systolic blood pressure (SBP) measures the pressure in the circulatory system when the heart beats and pumps blood. Diastolic blood pressure (DBP) measures the pressure in the circulatory system when the heart is resting between beats. Obesity is a significant risk factor for hypertension (high blood pressure). Obesity-related hypertension is often a precursor for coronary artery disease, heart failure, and chronic kidney disease (Jung and Ihm, 2023).

Liraglutide 3.0 mg (Saxenda)

Liraglutide was associated with greater improvements in SBP compared to control treatments among adults with overweight or obesity (Atlas et al., 2022).

Semaglutide 2.4 mg (Wegovy)

Semaglutide resulted in significant improvements in SBP (Davies et al., 2021; Lincoff et al., 2023; McGowan et al., 2024; Qin et al., 2024; Wadden et al., 2021) and DBP (Lincoff et al., 2023; Qin et al., 2024; Wadden et al., 2021) compared to control treatments among adults with overweight or obesity.

Tirzepatide (Zepbound)

Tirzepatide was linked to significant improvements in SBP and DBP compared to control treatments among adults with overweight or obesity (Jastreboff et al., 2022; Liu et al., 2024).

C-reactive protein level outcomes for GLP-1s

C-reactive protein (CRP) levels are a marker of inflammation in the body. Higher BMI is associated with higher CRP concentrations, suggesting low-grade systemic inflammation in people with overweight or obesity. Elevated CRP levels in people with overweight or obesity are associated with increased risk for health issues such as cardiovascular disease, type 2 diabetes, and other inflammatory conditions (Visser et al., 1999).

Liraglutide 3.0 mg (Saxenda)

CRP levels significantly decreased with the combination of liraglutide and exercise, but not with placebo, exercise alone, or liraglutide alone (Sandsdal et al., 2023),

Semaglutide 2.4 mg (Wegovy)

Semaglutide was associated with significant improvements in CRP levels compared to control treatments (Davies et al., 2021; Lincoff et al., 2023; Qin et al., 2024; Wadden et al., 2021).

Harms

Harms of FDA-approved GLP-1 AOMs

Liraglutide 3.0 mg (Saxenda)

Harms of liraglutide in adults: Gastrointestinal adverse events (AEs) such as nausea, vomiting, indigestion, loss of appetite, constipation, and diarrhea were more commonly experienced by liraglutide groups than control groups (Alkhezi et al., 2023; Atlas et al., 2022; Gudbergson et al., 2021; Shi et al., 2024). The odds of study withdrawal due to AEs were higher with liraglutide (Alkhezi et al., 2023; Shi et al., 2024). Liraglutide was also associated with higher rates of gallbladder-related and pancreatic AEs (Atlas et al., 2022).

A meta-analysis of 26 trials reported that GLP-1 treatments were associated with a significant increase in the risk of overall thyroid cancer compared to placebo; however, when isolating the meta-analysis to only include the six studies that involved liraglutide or semaglutide for the treatment of obesity in adults, the increased risk for overall thyroid cancer was not statistically significant (Silverii et al., 2024).

Harms of liraglutide in children and adolescents: Liraglutide did not increase total AEs compared to placebo among participants aged 5 to 18 years with obesity (Cornejo-Estrada et al., 2023).

Semaglutide 2.4 mg (Wegovy)

Harms of semaglutide in adults: The proportions of AEs (Qin et al., 2024; Wadden et al., 2021) and serious AEs (McGowan et al., 2024; Qin et al., 2024) were similar in both the semaglutide and control groups. Another study reported that serious AEs were more likely to be reported by the control group than the semaglutide group (Lincoff et al., 2023).

Semaglutide was more likely to cause gastrointestinal AEs such as nausea, vomiting, diarrhea, constipation, headache, loss of appetite, indigestion, and abdominal pain compared to control treatments (Alkhezi et al., 2023; McGowan et al., 2024; Qin et al., 2024; Shi et al., 2024; Wadden et al., 2021). Semaglutide had higher rates of AEs leading to discontinuation (Lincoff et al., 2023; McGowan et al., 2024; Qin et al., 2024; Shi et al., 2024).

Rates of cardiovascular disorders were significantly lower with semaglutide compared to control treatments (Qin et al., 2024). Semaglutide was the only GLP-1 associated with higher odds of causing headache and abdominal pain (Alkhezi et al., 2023).

A meta-analysis of 26 trials reported that GLP-1 treatments were associated with a significant increase in the risk of overall thyroid cancer compared to placebo; however, when isolating the meta-analysis to only include the six studies that involved liraglutide or semaglutide for the treatment of obesity in adults, the increased risk for overall thyroid cancer was not statistically significant (Silverii et al., 2024).

Harms of semaglutide in children and adolescents: The control group was more likely to report AEs than the semaglutide group; however, gastrointestinal AEs (primarily nausea, vomiting, and diarrhea) and serious AEs were more frequently reported by the semaglutide group (Weghuber et al., 2022).

Tirzepatide (Zepbound)

Harms of tirzepatide in adults: Tirzepatide participants were more likely to report AEs (but not serious AEs) than control treatment participants – the most commonly reported AEs were gastrointestinal, and withdrawal rates due to AEs were higher with tirzepatide (Jastreboff et al., 2022; Liu et al., 2024). Tirzepatide was more likely to cause nausea, vomiting, and loss of appetite than placebo – tirzepatide 10 mg was significantly more likely to cause constipation, and tirzepatide 15 mg was more likely to cause diarrhea and indigestion (Alkhezi et al., 2023).

Harms of tirzepatide in children and adolescents: Tirzepatide is not approved for use in children and adolescents.

Summary of findings regarding FDA-approved AOMs for adults: There is *very strong evidence* that FDA-approved GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) for chronic weight management are effective when used as adjuncts to usual care (which includes standard diet and activity and lifestyle recommendations) for adults. Use of these medications increases the amount of weight loss and percentage of body weight loss, and reduces BMI, compared to placebo or usual care alone.

GLP-1s also improved diabetic and cardiometabolic factors, blood pressure, and physical function compared to usual care.

Comparisons across the medications, as well as direct evidence, suggest that tirzepatide is more effective than semaglutide, which is more effective than liraglutide.

Figure 3. Evidence of Effectiveness of FDA-Approved AOMs for Adults



Summary of findings regarding FDA-approved AOMs for children and adolescents: There is *conflicting evidence* that AOMs improve weight loss in children and adolescents. For liraglutide, one meta-analysis reported that there was no statistically significant difference in weight loss or reduction in BMI, compared to placebo. Two studies reported that adolescents who received semaglutide had a greater improvement in BMI than adolescents who received a placebo.

Tirzepatide is not approved for use in children and adolescents.

Figure 4. Evidence of Effectiveness of FDA-Approved AOMs for Children and Adolescents



Intensive Behavioral Therapy

Effectiveness of IBT on weight management outcomes in adults

A systematic review commissioned by the U.S. Preventive Services Task Force (USPSTF) (LeBlanc et al., 2018) assessed the benefits and harms of IBT for weight loss in adults with above normal BMI. Pooled results from 67 RCTs of IBT for weight management in adults indicated that receiving IBT for weight loss was associated with a statistically significant greater weight loss compared to the control groups at 12 to 18 months. The systematic review also found that persons who received IBT were significantly more likely to lose 5% of their baseline weight compared to the control groups and that weight loss continued to be significantly greater among those who received IBT in interventions that lasted up to 36 months. Participants in the intervention groups also regained less weight than those in the control groups.

Effectiveness of IBT on weight management outcomes in children and adolescents

The American Academy of Pediatrics' clinical practice guideline regarding IBT for weight loss among children and adolescents with obesity references a systematic review of 42 trials conducted by O'Connor et al. (2017). The authors found a dose-response pattern where increased contact hours were associated with larger effects. After 6 to 12 months, differences in BMI change were typically statistically significant for interventions that involved 26 or more contact hours.

and typically not statistically significant for interventions with fewer contact hours. Participants in the intervention groups experienced reductions in BMI, whereas participants in the control groups experienced no changes in BMI or increases in BMI. The authors also assessed the impact of IBT on change in weight and found that participants who received IBT that involved 26 or more contact hours lost more weight than participants in control groups.

Outcomes related to diabetic factors in adults and children/adolescents

In a pooled analysis of nine trials, LeBlanc et al. (2018) determined that there was a significant reduction in the risk of developing type 2 diabetes over 1 to 9 years among adults who received IBT for weight loss compared with participants in comparison groups.

Among the studies of interventions that involved 52 or more contact hours, O'Connor et al. (2017) identified some improvements insulin and glucose measures but no changes in fasting plasma glucose or lipids for children and adolescents.

Outcomes related to cardiovascular factors in children/adolescents

In a pooled analysis of six studies, O'Connor et al. (2017) found that participants who received 52 or more contact hours of IBT had significantly greater improvements in SBP and DBP than participants in control groups.

Harms

LeBlanc et al. (2018) concluded that there were no serious harms associated with IBT for weight loss in adults. O'Connor et al. (2017) found no evidence of IBT for weight loss causing harm in children and adolescents.

FDA-Approved AOMs Versus IBT

Liraglutide 3.0 mg (Saxenda)

One RCT reported that liraglutide plus IBT in adults with overweight or obesity and without diabetes significantly increased percent weight loss relative to IBT alone at week 52 (Tronieri et al., 2020).

Semaglutide 2.4 mg (Wegovy)

One RCT found that semaglutide plus IBT in adults with overweight or obesity with at least one weight-related comorbid condition (not diabetes) resulted in significantly greater improvements in body weight, waist circumference, and BMI, and significantly more participants achieving $\geq 5\%$, $\geq 10\%$, $\geq 15\%$, and $\geq 20\%$ weight loss after 68 weeks compared to placebo plus IBT (Wadden et al., 2021).


Summary of findings regarding intensive behavioral therapy for adults: There is *very strong* evidence that IBT for weight loss is effective in reducing weight and BMI in adults based on one systematic review. Participants who received IBT were significantly more likely to lose weight and achieve a $\geq 5\%$ weight loss, as well as have a reduced risk of developing type 2 diabetes, than participants who received a controlled intervention.

Figure 5. Evidence of Effectiveness of Intensive Behavioral Therapy for Adults



Summary of findings regarding intensive behavioral therapy for children and adolescents: There is *very strong evidence* that IBT for weight loss is effective in reducing weight and BMI in adults based on one systematic review. Participants who received IBT were significantly more likely to lose weight and achieve a $\geq 5\%$ weight loss, as well as have a reduced risk of developing type 2 diabetes, than participants who received a controlled intervention.

Figure 6. Evidence of Effectiveness of Intensive Behavioral Therapy for Children and Adolescents



Summary of Findings

The evidence for the medical effectiveness of IBT and FDA-approved GLP-1 AOMs indicated for chronic weight management in patients with obesity is summarized below in Table 6.

Table 6. Summary of Evidence of Medical Effectiveness of Treatments for Chronic Weight Management

Type of Weight Management Intervention	Impact of Intervention on Weight Management	Impact of Intervention on Other Health Outcomes	Comparison of Interventions
FDA-approved GLP-1 AOMs for adults	<i>Very strong evidence</i> that use of FDA-approved GLP-1 AOMs combined with usual care (including diet and activity and lifestyle recommendations) results in greater weight loss than usual care alone.	<i>Very strong evidence</i> of improvement in HRQOL, physical functioning, cardiometabolic health, blood pressure, and HbA1c with GLP-1s.	Comparisons across GLP-1s suggest that tirzepatide achieves greater weight loss than semaglutide which achieves greater weight loss than liraglutide.
FDA-approved GLP-1 AOMs for children and adolescents	<i>Conflicting evidence</i> regarding the impact of FDA-approved GLP-1 AOMs for children and adolescents. <i>Some evidence</i> that semaglutide improves weight loss and <i>some evidence</i> that liraglutide is not associated with improved weight loss. Tirzepatide is not approved for use in children and adolescents.	<i>Some evidence</i> that semaglutide improves HRQOL and physical functioning. <i>Some evidence</i> that liraglutide did not increase hypoglycemic episodes.	CHBRP did not identify any studies that directly compared the effectiveness of GLP-1 AOMs among children and adolescents.
IBT for adults	<i>Very strong evidence</i> that IBT for adults is associated with significantly greater weight loss.	<i>Very strong evidence</i> that IBT is associated with reduced risk of developing type 2 diabetes.	<i>Very strong evidence</i> that IBT for weight management is more effective than usual care, no intervention, minimal intervention, and being waitlisted for an intervention.
IBT for children and adolescents	<i>Very strong evidence</i> that IBT for weight management is effective in reducing weight and BMI for children and adolescents. IBT interventions with 26 or more hours of contact are more likely to yield greater weight loss compared to IBT interventions with fewer contact hours.	<i>Very strong evidence</i> that IBT is greater improvements in diabetes and blood pressure control.	<i>Very strong evidence</i> that IBT for weight loss is more effective than usual care, no intervention, minimal intervention, and being waitlisted for an intervention.

Source: California Health Benefits Review Program, 2025.

Key: AOM = anti-obesity medication; BMI = body mass index; CHBRP = California Health Benefits Review Program; FDA = U.S. Food and Drug Administration; GLP-1 = glucagon-like peptide-1; HbA1c = hemoglobin A1c; HRQOL = health-related quality of life; IBT = intensive behavioral therapy.

[Back to Table of Contents](#)

Benefit Coverage, Utilization, and Cost Impacts

As discussed in the *Policy Context* section, AB 575 would require health plans and health policies regulated by the Department of Managed Health Care (DMHC) or the California Department of Insurance (CDI) to cover intensive behavioral therapy (IBT) and at least one glucagon-like peptide-1 (GLP-1) receptor agonist without prior authorization for the treatment or prevention of obesity. In addition, AB 575 prohibits coverage criteria from being more restrictive than the U.S. Food and Drug Administration (FDA)-approved indications for those treatments.

This section reports the potential incremental impacts of AB 575 on estimated baseline benefit coverage, utilization, and overall cost.

Analytic Approach and Key Assumptions

As stated in the *Policy Context* section, this cost analysis is based on the interpretation that only GLP-1 drugs with an FDA indication for the treatment of obesity would be covered by this mandate. Only three GLP-1 drugs approved for chronic weight management are currently relevant to this mandate: liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound). GLP-1 drugs used to treat diabetes (e.g., Ozempic, Mounjaro) are not included in this analysis.

The data sources, approach, and key assumptions used to analyze AB 535 are available in Appendix D. However, there are several notable assumptions related to the cost analysis provided here:



How does utilization impact premiums?

Health insurance, by design, distributes risk and expenditures across everyone enrolled in a plan or policy. It does so to help protect each enrollee from the full impact of health care costs that arise from that enrollee's use of prevention, diagnosis, and/or treatment of a covered medical condition, disease, or injury. Changes in utilization among any enrollees in a plan or policy can result in changes to premiums for all enrollees in that plan or policy.

Intensive Behavioral Therapy

1. The number of enrollees using intensive behavioral therapy (IBT) at baseline was increased by a factor of two to account for the assumption that 50% of IBT is reimbursed to vendors through contracts that do not result in paid claims that appear in claims databases. The remainder of IBT is typically provided by vendors through capitation and results in encounter reporting.
2. Unit cost is based upon publicly available information from the Centers for Disease Control and Prevention (CDC), estimating that the cost per enrollee per year of a Diabetes Prevention Program (DPP) is \$500. Note that DPP is the "gold standard" of IBT, therefore CHBRP assumed that most IBT was equivalent in price to DPP.³⁸
3. CHBRP assumed that cost sharing for IBT was \$0 if covered by the health plan/insurer at baseline due to being considered a preventive service.

GLP-1 Medications

1. Previous barriers to obtaining GLP-1 medications due to supply chain problems would no longer constrain provider prescribing or patient access to GLP-1 medications for treatment of obesity. Due to resolution of supply chain barriers, the FDA will no longer allow compounding by third-party compounding pharmacies as of April 2025.

³⁸ Communication with content expert, D. Thiara, MD, March 2025.

2. The utilization of GLP-1 medications by enrollees postmandate would be similar to the use of GLP-1 medications in the 2024 pharmacy claims data from Milliman's MyRxConsultant for a national self-insured employer that already offers coverage for these medications and has offered such coverage for several years. This dataset provides a stable benchmark to understand what happens when a plan newly offers GLP-1 drugs to their covered population, and how use increases over multiple years.
3. CHBRP estimated that 7.5% of enrollees with obesity and full coverage by their health plan would use these medications in year 1 and 11.3% in year 2. This is due to a 50% increase from Year 1 to Year 2, based upon pharmacy claims data from Milliman's MyRxConsultant (see #2 above) which demonstrates how utilization changes year-over-year after GLP-1 medications are covered.
4. CHBRP estimated that 1.8% of individuals without coverage would self-pay for these medications at baseline. This information is based upon CHBRP's interpretation of a Kaiser Family Foundation (KFF) Survey focused on GLP-1 accessibility and knowledge.
5. The unit cost for GLP-1 medications would be equivalent to the direct-to-consumer programs³⁹ (\$499 per 1-month supply) available to cash pay or patients without coverage for the medications through their health insurance. Both Wegovy and Zepbound have direct-to-consumer programs with the same per unit cost, and CHBRP assumes that negotiations between insurance carriers, their pharmacy benefit managers, and manufacturers will lead to a price point net of rebates of \$499 for a 1-month supply. CHBRP assumed that the \$499 unit cost for GLP-1 medications would not change due to AB 575.
 - a. AB 575 requires the coverage of at least one GLP-1 drug for treatment of obesity. CHBRP assumed that health plans and health insurance policies that are noncompliant with the mandate will choose to cover the lowest priced options, which in this case will be the two newer, weekly GLP-1 medications (Wegovy and Zepbound). Because Saxenda, which is also manufactured by the same company that makes Wegovy (Novo Nordisk) has been on the market longer, is a daily regimen, has more side effects than Zepbound, and maintains a higher price point, CHBRP assumed that health plans and insurance policies would not rely on Saxenda to comply with AB 575. There is also a generic version of liraglutide (Victoza) that is indicated for management of obesity with type 2 diabetes (similar to Ozempic). Due to Victoza's indication for diabetes, and because the generic version still ranges from \$350 to \$700 per 30-day supply (vs. the \$499 cost of Zepbound/Wegovy), CHBRP concluded that the generic liraglutide would be an unlikely replacement for a GLP-1 AOM for purposes of compliance with AB 575.
6. CHBRP assumed that cost sharing would be similar to average cost sharing (or average coinsurance) for a typical plan design within each metal level or deductible level. CHBRP assumed that cost sharing for IBT was \$0 if indicated in the survey of health plans and insurers at baseline.
7. CHBRP assumed that medical costs in year 2 would be reduced by \$100 per GLP-1 user per year due to a reduction in risk of heart failure and attributable emergency department visits and hospitalizations. This assumption is based upon data that heart failure risk decreased after 12-18 months of treatment, resulting in a Year 2 impact only (Packer et al., 2025; Sattar et al., 2021).
8. CHBRP assumed that the prohibition of prior authorization requirements by AB 575 would increase access to GLP-1 medications. However, CHBRP anticipates that health plans and insurance policies would continue using utilization management techniques, which may include step therapy, lab result requirements, or other processes to reduce non-approved use of GLP-1 medications.

Almost all – 96.2% – commercial/California Public Employees' Retirement System (CalPERS) enrollees in plans and policies regulated by DMHC or CDI have a pharmacy benefit regulated by DMHC or CDI that covers both generic and

³⁹ Direct-to-consumer programs are used by manufacturers to provide discounted prices to consumers who do not have coverage for a medication or who do not have insurance at all and have to pay out-of-pocket. One example is the [LillyDirect Self Pay Pharmacy Solution](#).

brand-name outpatient prescription medications.⁴⁰ Of the remaining commercial/CalPERS enrollees, 1.2% do not have a pharmacy benefit and 2.6% have a pharmacy benefit that is not regulated by DMHC or CDI. Because AB 575 does not require creation of a pharmacy benefit – only compliant benefit coverage when a pharmacy benefit is present – baseline benefit coverage for enrollees without a pharmacy benefit or whose pharmacy benefit is not regulated by DMHC or CDI is assumed to be compliant.

For further details on the underlying data sources and methods used in this analysis, please see Appendix C.

Baseline and Postmandate Benefit Coverage

As discussed in the *Policy Context* section, AB 575 would apply to state-regulated health insurance, including commercial enrollees and enrollees with insurance through the CalPERS. It should be noted that DMHC regulates the plans and policies of approximately 74% of enrollees associated with CalPERS, in addition to commercial enrollees.⁴¹

CHBRP estimates that at baseline, 11.21 million Californians (82.6%) with state-regulated insurance subject to the mandate are enrolled in plans or policies that do not currently cover a GLP-1 indicated for chronic weight management, as required by AB 575, and 2.36 million (17.4%) are enrolled in plans or policies that are compliant. Approximately 30,000 enrollees (0.2%) do not have coverage for IBT as required by AB 575. There are 13.54 million enrolled (99.8%) in plans or policies that are compliant with the IBT requirement in AB 575.

Baseline coverage of GLP-1 would increase substantially due to AB 575 postmandate. The increase in IBT coverage from baseline is much smaller, due to existing coverage of IBT for the vast majority of enrollees.

Below, Table 7 provides estimates of how many Californians have health insurance that would have to comply with AB 575 in terms of benefit coverage. Despite AB 575 removing prior authorization for GLP-1 and IBT, CHBRP assumed different methods of limiting access to services using utilization management would still be allowed. Therefore, Table 7 does not provide information on prior authorization requirements at baseline.

Table 7. Impacts of AB 575 on Benefit Coverage, 2026

	Baseline (2026)	Postmandate Year 1 (2026)	Increase/Decrease	Change Postmandate
Total enrollees with health insurance subject to state benefit mandates*	22,207,000	22,207,000	0	0.00%
Total enrollees with health insurance subject to AB 575	13,570,000	13,570,000	0	0.00%
Enrollees with coverage for obesity treatments				
Percentage of enrollees with coverage for GLP-1 medications	17.4%	100.0%	82.6%	476.12%
Percentage of enrollees with coverage for IBT	99.8%	100.0%	0.2%	0.22%
Enrollees without coverage for obesity treatments				

⁴⁰ For more detail, see CHBRP's [resource](#) *Pharmacy Benefit Coverage in State-Regulated Health Insurance*.

⁴¹ For more detail, see CHBRP's [resource](#), *Sources of Health Insurance in California*.

	Baseline (2026)	Postmandate Year 1 (2026)	Increase/Decrease	Change Postmandate
Percentage of enrollees without coverage for GLP-1 medications	82.6%	0.0%	-82.6%	-100.00%
Percentage of enrollees without coverage for IBT	0.2%	0.0%	-0.2%	-100.00%

Source: California Health Benefits Review Program, 2025.

Notes: * Enrollees in plans and policies regulated by DMHC or CDI. Includes those associated with Covered California, CalPERS, or Medi-Cal.⁴²

Key: AOM = anti-obesity medication; CalPERS = California Public Employees' Retirement System; CDI = California Department of Insurance; DMHC = Department of Managed Health Care; IBT = intensive behavioral therapy.

Baseline and Postmandate Utilization and Unit Cost

Use of GLP-1 medications and IBT would increase postmandate due to AB 575. Due to the expansion in coverage of GLP-1 medications by health plans and policies postmandate (82.6% of enrollees would gain new coverage), there would be an accompanying increase in use of GLP-1 medications by enrollees, and a reduction in the number of self-pay enrollees using GLP-1 medications due to lack of coverage. In total, CHBRP estimates an additional 182,520 enrollees would utilize GLP-1 medications postmandate. The increase in IBT use would be approximately 35 enrollees in Year 1; there is a high level of baseline coverage (99.8%) for this treatment.

Average cost sharing for GLP-1 medications would increase by 17.05% postmandate (\$10 per 1-month supply) due to the additional coverage required by AB 575 and the increased use of GLP-1 medications. Average cost sharing for IBT would stay consistent at approximately \$2 per enrollee.

No impact on unit cost is expected due to AB 575. CHBRP estimates the unit cost of \$499 for GLP-1 medications, which aligns with the current manufacturer's "direct-to-consumer" savings program would be maintained during the 2 years of this analysis.

Below, Table 8 provides estimates of the impacts of AB 575 on utilization and unit cost of IBT and GLP-1 medications.

Table 8. Impacts of AB 575 on Utilization and Unit Cost, 2026

	Baseline (2026)	Postmandate Year 1 (2026)	Increase/ Decrease	Change Postmandate
Eligible populations				
Number of enrollees with obesity	3,065,012	3,065,012	—	0.00%
Number of overweight enrollees with comorbidities	756,350	756,350	—	0.00%
Utilization with coverage				
Number of enrollees using GLP-1 AOM	37,632	220,151	182,520	485.02%
Number of enrollees receiving IBT	16,281	16,316	35	0.22%
Utilization without coverage				
Number of enrollees using GLP-1 AOM	42,813	—	(42,813)	-100.00%

⁴² For more detail, see CHBRP's [resource](#), *Sources of Health Insurance in California*.

	Baseline (2026)	Postmandate Year 1 (2026)	Increase/ Decrease	Change Postmandate
Number of enrollees receiving IBT	—	—	—	0.00%
Average unit cost				
Average unit cost of GLP-1 AOM (30-day supply)	\$499	\$499	\$0	0%
Average unit cost of IBT (1 year of therapy)	\$500	\$500	\$0	0%
Average cost sharing				
Average cost sharing for GLP-1 AOM	\$57.75	\$67.60	\$9.85	17.05%
Average cost sharing for IBT	\$2.07	\$2.22	\$0.15	7.36%

Source: California Health Benefits Review Program, 2025.

Key: AOM = anti-obesity medication; GLP-1 = glucagon-like peptide-1; IBT = intensive behavioral therapy.

Baseline and Postmandate Expenditures

For DMHC-regulated plans and CDI-regulated policies, AB 575 would increase total premiums paid by employers and enrollees for newly covered benefits. Enrollee expenses for covered benefits would increase, while those for noncovered benefits would decrease. This would result in an increase of total net annual expenditures for enrollees with DMHC-regulated plans and CDI-regulated policies


CHBRP estimates total expenditures would increase by \$913,986,000 (0.53%) due to AB 575, with the majority attributable to increased coverage of GLP-1 medications. Notably, expenditures for noncovered benefits at baseline will decrease by over \$256 million due to new GLP-1 coverage postmandate (Figure 7).

Below, Table 9 provides estimates of the impacts of AB 575 on expenditures, which include premiums, enrollee cost sharing, and enrollee expenses for noncovered benefits.

Table 9. AB 575 Impacts on Expenditures, 2026

	Baseline (2026)	Postmandate Year 1 (2026)	Increase/Decrease	Percentage Change
Premiums				
Employer-sponsored (a)	\$68,752,638,000	\$69,341,666,000	\$589,028,000	0.86%
CalPERS employer (b)	\$7,881,873,000	\$7,943,899,000	\$62,026,000	0.79%
Medi-Cal (excludes COHS) (c)	\$31,818,731,000	\$31,818,731,000	\$0	0.00%

Figure 7. Expenditure Impacts of AB 575



Source: California Health Benefits Review Program, 2025.

Key: DMHC = Department of Managed Health Care.

	Baseline (2026)	Postmandate Year 1 (2026)	Increase/Decrease	Percentage Change
Enrollee premiums (expenditures)				
Enrollees, individually purchased insurance	\$21,757,790,000	\$21,940,088,000	\$182,298,000	0.84%
Outside Covered California	\$6,011,399,000	\$6,053,743,000	\$42,344,000	0.70%
Through Covered California	\$15,746,391,000	\$15,886,345,000	\$139,954,000	0.89%
Enrollees, group insurance (d)	\$21,712,866,000	\$21,897,367,000	\$184,501,000	0.85%
Enrollee out-of-pocket expenses				
Cost-sharing for covered benefits (deductibles, copayments, etc.)	\$18,992,422,000	\$19,144,921,000	\$152,499,000	0.80%
Expenses for noncovered benefits (e) (f)	\$256,366,000	\$0	-\$256,366,000	-100.00%
Total expenditures	\$171,172,686,000	\$172,086,672,000	\$913,986,000	0.53%

Source: California Health Benefits Review Program, 2025.

Notes: (a) In some cases, a union or other organization. Excludes CalPERS.

(b) Includes only CalPERS enrollees in DMHC-regulated plans. Approximately 54.0% are state retirees, state employees, or their dependents. About one in five (20.5%) of these enrollees has a pharmacy benefit not subject to DMHC. CHBRP has projected no impact for those enrollees. However, CalPERS could, postmandate, require equivalent coverage for all its members (which could increase the total impact on CalPERS).

(c) Includes only Medi-Cal beneficiaries enrolled in DMHC-regulated plans. In addition, CHBRP is estimating it seems likely that there would also be a proportional increase of \$0 million for Medi-Cal beneficiaries enrolled in COHS managed care.

(d) Enrollee premium expenditures include contributions by enrollees to employer (or union or other organization)-sponsored health insurance, health insurance purchased through Covered California, and any contributions to enrollment through Medi-Cal to a DMHC-regulated plan.

(e) Includes only expenses paid directly by enrollees (or other sources) to providers for services related to the mandated benefit that are not covered by insurance at baseline. This only includes those expenses that will be newly covered postmandate. Other components of expenditures in this table include all health care services covered by insurance.

(f) For covered benefits, such expenses would be eliminated, although enrollees with newly compliant benefit coverage might pay some expenses if benefit coverage is denied (through utilization management review).

Key: CalPERS = California Public Employees' Retirement System; CDI = California Department of Insurance; COHS = County Organized Health Systems; DMHC = Department of Managed Health Care

Premiums

At the end of this section, Table 10 and Table 11 present baseline and postmandate expenditures by market segment for DMHC-regulated plans and CDI-regulated policies. The tables present per member per month (PMPM) premiums, enrollee expenses for both covered and noncovered benefits, and total expenditures (premiums as well as enrollee expenses).

Changes in premiums as a result of AB 575 would vary by market segment. Note that such changes are related to the number of enrollees (see Table 7, Table 10, and Table 11), with health insurance that would be subject to AB 575.

Commercial

The largest premium increases will occur in the DMHC-regulated commercial market, ranging from a 0.9136% increase for the DMHC-regulated small group to a 0.851% increase in the DMHC-regulated individual market. The CDI-regulated large-group market would face the smallest increase due to AB 575, which is 0.1613%.

Premiums would increase by 0.8888% for DMHC-regulated Covered California individual market plan enrollees, and mirror plans available to individuals outside of Covered California would see an increase in premiums of 0.7044%.

CalPERS

For enrollees associated with CalPERS in DMHC-regulated plans, premiums would increase by 0.7869%.

Enrollee Expenses

AB 575–related changes in cost sharing for covered benefits (deductibles, copays, etc.) and out-of-pocket expenses for noncovered benefits would vary by market segment. Note that such changes are related to the number of enrollees (see Table 7, Table 10, and Table 11) with health insurance that would be subject to AB 575 expected to use the relevant treatments during the year after enactment.

CHBRP projects no change to copayments or coinsurance rates but does project an increase in utilization of GLP-1 drugs and therefore an increase in enrollee cost sharing.

It is possible that some enrollees incurred expenses related to treatments for which coverage was denied, but CHBRP cannot estimate the frequency with which such situations occur and so cannot offer a calculation of impact. However, CHBRP does estimate that enrollees purchasing GLP-1 medications through self-pay due to the lack of coverage at baseline would result in a \$256.4 million decrease in enrollee spending on noncovered benefits.

The largest decreases in enrollee spending related to noncovered benefits will occur in the DMHC-regulated individual market (\$2.14), whereas there is no change in the CDI-regulated individual market (\$0.00).

Per-user enrollee expenses

The impact of AB 575 on cost sharing would vary depending on a number of factors, including coverage of the medication at baseline, as well as an enrollee's choice to pay out-of-pocket for noncovered benefits. Therefore, enrollee expense would vary.

Example 1: Elimination of self-pay. AB 575 may result in a complete elimination of self-pay for an enrollee who gains coverage. At baseline, this enrollee could pay \$5,988 annually ($12 \times \499 per 30-day supply) under direct access programs from manufacturers. Postmandate, enrollee expenditures would vary depending on the plan design. Enrollees in relatively rich copay plans without a deductible (for example, a \$50 copay for a brand medication) may pay \$600 annually ($12 \times \50 per copay). Enrollees in high deductible health plans may still see cost sharing of \$3,000 or more per year, depending on the deductible.

Example 2: No cost-sharing change. For enrollees with coverage at baseline, AB 575 would not result in any changes in cost-sharing.

Example 3: Increase in cost sharing. For enrollees who experienced a denial in coverage at baseline due to prior authorization requirements, these individuals would have had no cost sharing at baseline. If these enrollees obtained coverage postmandate, they could see increases in cost sharing. Enrollee expenditures would vary depending on the plan design. Enrollees in relatively rich copay plans without a deductible (for example, a \$50 copay for a brand drug) may pay \$600 annually ($12 \times \50 per copay). Enrollees in high deductible health plans may see cost sharing of \$3,000 or more per year, depending on the deductible.

Postmandate Administrative and Other Expenses

CHBRP estimates that the increase in administrative costs of DMHC-regulated plans and/or CDI-regulated policies will remain proportional to the increase in premiums. CHBRP assumes that if health care costs increase as a result of increased utilization or changes in unit costs, there is a corresponding proportional increase in administrative costs. CHBRP assumes that the administrative cost portion of premiums is otherwise unchanged. All health plans and insurers impacted by this mandate include a component for administration and profit in their premiums.

Other Considerations for Policymakers

In addition to the impacts a bill may have on benefit coverage, utilization, and cost, related considerations for policymakers are discussed below.

Postmandate Changes in the Number of Uninsured Persons

CHBRP assumes that if premiums increase by more than 1% in any market segment, some enrollees will lapse their coverage. Because the change in average premiums does not exceed 1% for any market segment (see Table 9, Table 10, and Table 11) in Year 1, CHBRP would expect no measurable change in the number of uninsured persons due to the enactment of AB 575. However, the premium increase in Year 2 as additional enrollees obtain GLP-1 medications will be above 1% in all but one market segment, resulting in 12,600 newly uninsured people in 2027 (Appendix D, Table 15). Note that

Second-Year Expenditures

Table 15 provides second-year estimates of the impacts of AB 575 on expenditures, which include premiums, enrollee cost sharing, and enrollee expenses for noncovered benefits. For DMHC-regulated plans and CDI-regulated policies, AB 575 would increase total premiums paid by employers and enrollees for newly covered benefits. Enrollee expenses noncovered benefits would decrease, however cost sharing would increase. Overall, second-year expenditures would be anticipated to be higher than first-year expenditures.

Table 15 does not include the incremental cost impact from disenrolling enrollees who are newly uninsured as a result of the premium changes.

Changes in Public Program Enrollment

CHBRP estimates that the mandate would produce no measurable impact on enrollment in publicly funded insurance programs due to the enactment of AB 575.

How Lack of Benefit Coverage Results in Cost Shifts to Other Payers

There does not appear to be cost shifting to other public payers or programs at baseline.

[Back to Table of Contents](#)

Table 10. Baseline Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2026

	DMHC-Regulated						CDI-Regulated			Total
	Commercial Plans (by Market) (a)			Publicly Funded Plans			Commercial Policies (by Market) (a)			
	Large Group	Small Group	Individual	CalPERS (b)	Medi-Cal (Excludes COHS) (c)		Large Group	Small Group	Individual	
					Under 65	65+				
Enrollee counts										
Total enrollees in plans/policies subject to state mandates (d)	8,034,000	2,076,000	2,181,000	914,000	7,787,000	850,000	264,000	65,000	36,000	22,207,000
Total enrollees in plans/policies subject to AB 575	8,034,000	2,076,000	2,181,000	914,000	0	0	264,000	65,000	36,000	13,570,000
Premiums										
Average portion of premium paid by employer (e)	\$557.33	\$507.76	\$0.00	\$718.62	\$276.79	\$583.72	\$609.11	\$567.83	\$0.00	\$108,453,242,000
Average portion of premium paid by enrollee	\$145.58	\$212.63	\$818.51	\$139.09	\$0.00	\$0.00	\$224.25	\$185.49	\$777.47	\$43,470,656,000
Total premium	\$702.91	\$720.39	\$818.51	\$857.71	\$276.79	\$583.72	\$833.35	\$753.32	\$777.47	\$151,923,898,000
Enrollee expenses										
Cost sharing for covered benefits (deductibles, copays, etc.)	\$64.42	\$164.36	\$272.54	\$81.59	\$0.00	\$0.00	\$122.99	\$249.30	\$173.93	\$18,992,422,000
Expenses for noncovered benefits (f)	\$1.45	\$1.71	\$2.14	\$1.46	\$0.00	\$0.00	\$0.32	\$0.65	\$0.00	\$256,366,000
Total expenditures	\$768.79	\$886.45	\$1,093.19	\$940.76	\$276.79	\$583.72	\$956.66	\$1,003.27	\$951.40	\$171,172,686,000

Source: California Health Benefits Review Program, 2025.

Notes: (a) Includes enrollees with grandfathered and nongrandfathered health insurance acquired outside or through Covered California (the state's health insurance marketplace).

(b) Includes only CalPERS enrollees in DMHC-regulated plans. Approximately 51.6% are state retirees, state employees, or their dependents. About one in five (20.5%) of these enrollees has a pharmacy benefit not subject to DMHC.⁴³ CHBRP has projected no impact for those enrollees. However, CalPERS could, postmandate, require equivalent coverage for all its members (which could increase the total impact on CalPERS).

(c) Includes only Medi-Cal beneficiaries enrolled in DMHC-regulated plans. Includes those who are also Medicare beneficiaries.

(d) Enrollees in plans and policies regulated by DMHC or CDI. Includes those associated with Covered California, CalPERS, or Medi-Cal.⁴⁴

(e) In some cases, a union or other organization – or Medi-Cal for its beneficiaries.

(f) Includes only those expenses that are paid directly by enrollees (or other sources) to providers for services related to the mandated benefit that are not covered by insurance at baseline. This only includes those expenses that will be newly covered, postmandate. Other components of expenditures in this table include all health care services covered by insurance.

Key: CalPERS = California Public Employees' Retirement System; CDI = California Department of Insurance; COHS = County Organized Health Systems; DMHC = Department of Managed Health Care.

⁴³ For more detail, see CHBRP's [resource](#) *Pharmacy Benefit Coverage in State-Regulated Health Insurance*.

⁴⁴ For more detail, see CHBRP's [resource](#) *Sources of Health Insurance in California*.

Table 11. Postmandate Change in Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2026

	DMHC-Regulated						CDI-Regulated			Total
	Commercial Plans (by Market) (a)			Publicly Funded Plans			Commercial Policies (by Market) (a)			
	Large Group	Small Group	Individual	CalPERS (b)	Medi-Cal (Excludes COHS) (c)		Large Group	Small Group	Individual	
					Under 65	65+				
Enrollee counts										
Total enrollees in plans/policies subject to state mandates (d)	8,034,000	2,076,000	2,181,000	914,000	7,787,000	850,000	264,000	65,000	36,000	22,207,000
Total enrollees in plans/policies subject to AB 575	8,034,000	2,076,000	2,181,000	914,000	0	0	264,000	65,000	36,000	13,570,000
Premiums										
Average portion of premium paid by employer (e)	\$4.8640	\$4.6392	\$0.0000	\$5.6552	\$0.0000	\$0.0000	\$0.9824	\$1.8157	\$0.0000	\$651,054,000
Average portion of premium paid by enrollee	\$1.2706	\$1.9427	\$6.9654	\$1.0946	\$0.0000	\$0.0000	\$0.3617	\$0.5931	\$0.0000	\$366,799,000
Total premium	\$6.1346	\$6.5818	\$6.9654	\$6.7497	\$0.0000	\$0.0000	\$1.3441	\$2.4088	\$0.0000	\$1,017,853,000
Enrollee expenses										
Cost sharing for covered benefits (deductibles, copays, etc.)	\$0.5585	\$1.4871	\$2.3062	\$0.0000	\$0.0000	\$0.0000	\$0.1976	\$0.7950	\$0.0000	\$152,499,000
Expenses for noncovered benefits (f)	-\$1.4549	-\$1.7074	-\$2.1422	-\$1.4566	\$0.0000	\$0.0000	-\$0.3237	-\$0.6460	\$0.0000	-\$256,366,000
Total expenditures	\$5.2382	\$6.3615	\$7.1295	\$5.2931	\$0.0000	\$0.0000	\$1.2180	\$2.5578	\$0.0000	\$913,986,000
Postmandate percent change										
Percent change insured premiums	0.8727%	0.9136%	0.8510%	0.7869%	0.0000%	0.0000%	0.1613%	0.3198%	0.0000%	0.6700%
Percent change total expenditures	0.6814%	0.7176%	0.6522%	0.5626%	0.0000%	0.0000%	0.1273%	0.2549%	0.0000%	0.5340%

Source: California Health Benefits Review Program, 2025.

Notes: (a) Includes enrollees with grandfathered and nongrandfathered health insurance acquired outside or through Covered California (the state's health insurance marketplace).

(b) Includes only CalPERS enrollees in DMHC-regulated plans. Approximately 51.6% are state retirees, state employees, or their dependents. About one in five (20.5%) of these enrollees has a pharmacy benefit not subject to DMHC.⁴⁵ CHBRP has projected no impact for those enrollees. However, CalPERS, postmandate, could require equivalent coverage for all its members (which could increase the total impact on CalPERS).

(c) Includes only Medi-Cal beneficiaries enrolled in DMHC-regulated plans. Includes those who are also Medicare beneficiaries.

(d) Enrollees in plans and policies regulated by DMHC or CDI. Includes those associated with Covered California, CalPERS, or Medi-Cal.⁴⁶

(e) In some cases, a union or other organization, or Medi-Cal for its beneficiaries.

(f) Includes only those expenses that are paid directly by enrollees (or other sources) to providers for services related to the mandated benefit that are not covered by insurance at baseline. This only includes those expenses that will be newly covered, postmandate. Other components of expenditures in this table include all health care services covered by insurance.

Key: CalPERS = California Public Employees' Retirement System; CDI = California Department of Insurance; COHS = County Organized Health Systems; DMHC = Department of Managed Health Care.

⁴⁵ For more detail, see CHBRP's [resource](#) *Pharmacy Benefit Coverage in State-Regulated Health Insurance*.

⁴⁶ For more detail, see CHBRP's [resource](#) *Sources of Health Insurance in California*.

Public Health Impacts

As discussed in the *Policy Context* section, AB 575 would require an individual or group health care service plan contract or health insurance policy that provides coverage for outpatient prescription drug benefits, to include coverage for at least one glucagon-like peptide-1 (GLP-1) U.S. Food and Drug Administration (FDA)-approved for weight loss, and intensive behavioral therapy (IBT) for the treatment of obesity without prior authorization.

The public health impact analysis includes estimated impacts in the short term (within 12 months of implementation) and in the long term (beyond the first 12 months postmandate). This section estimates the short-term impact⁴⁷ of AB 575 on change in body weight and additional health-related outcomes, barriers to diagnosis and treatment, potential treatment harms, and potential disparities. See the *Long-Term Impacts* section for discussion of premature death, economic loss, and social drivers of health.

Estimated Public Health Outcomes

Measurable health outcomes relevant to AB 575 include primary outcomes such as change in body weight of 5%, 10%, 15%, or 20%, percent excessive weight loss, and mean body mass index (BMI) change. Additional health-related outcomes included diabetes risk, glycated hemoglobin, systolic blood pressure, diastolic blood pressure, waist circumference, functional quality of life, and harms of FDA-approved GLP-1 weight management medications.

As presented in the *Medical Effectiveness* section, there is *very strong evidence* that FDA-approved GLP-1 anti-obesity medications (AOMs), and IBT are both effective for weight management in adults. The evidence is not as strong for children and adolescents, where there is *some evidence* for FDA-approved GLP-1s, although this varies by specific drug, and *very strong evidence* for intensive behavioral therapy.

As presented in the *Benefit Coverage, Utilization, and Cost Impacts* section, at baseline, it is estimated that among enrollees with health insurance that would be subject to AB 575, there are currently fairly high levels of coverage for IBT (99.8%) and relatively low levels of AB 575-compliant coverage for FDA-approved GLP-1 AOMs (17.4%).

It is estimated that as a result of AB 575, **utilization of obesity treatments would increase** as follows for the approximately 13.6 million enrollees (36% of all Californians) with health insurance that would be subject to AB 575:

- 182,520 enrollees using FDA-approved GLP-1s AOMs; and
- 35 enrollees receiving intensive behavioral therapy (IBT) for weight loss.

Based on the literature review presented in *Medical Effectiveness* section, it is estimated that across these 182,520 new utilizers of obesity treatments, they would have an average weight loss of between 5% and 21% compared to nonutilizers. The level of weight loss would depend on a number of factors including the specific treatment utilized and specific patient-level factors. In addition, there would be, on average, some level of improvement in obesity-related health outcomes such as decreased diabetes risk and improvement in hemoglobin (A1C) levels, improvement in blood pressure, reduced risk of cardiovascular events, and improved functional quality of life.

In the first year postmandate, 13.6 million enrollees with health insurance subject to AB 575 would experience a change in benefit coverage and 182,520 would newly utilize obesity treatments. As a result, these enrollees would experience a 5% to 21% reduction in body weight by and related health improvements, which is supported by evidence that obesity treatments are medically effective.

⁴⁷ CHBRP defines short-term impacts as changes occurring within 12 months of bill implementation.

Potential Harms From AB 575

When data are available, CHBRP estimates the marginal change in relevant harms associated with interventions affected by the proposed mandate. In the case of AB 575, there is evidence to suggest that an increase in the use of obesity treatments could result in harm. Potential harms associated with the use of FDA-approved medications for weight management include gastrointestinal-related symptoms, including nausea, vomiting, constipation, diarrhea, and dyspepsia (i.e., discomfort or pain in the upper abdomen); paresthesia (i.e., burning or prickling sensation, often occurring in the hands, arms, legs, or feet); dry mouth; insomnia; irritability; anxiety; headache; and increased blood pressure and heart rate. Adverse events may contribute to discontinuation of the drug, which can impact overall medical effectiveness of the treatment. It is unclear if long-term use is associated with more severe and persistent harms.

Impact on Disparities⁴⁸

As described in the *Background* section, there are many factors that serve as barriers to seeking and accessing obesity treatments. These barriers can serve to create disparities in rates of utilization of obesity treatments and overall rates of obesity. Each of these factors and the impact that AB 575 may have on addressing these barriers and resulting disparities is described below.

- **Stigma:** It is unclear how AB 575 would impact stigma surrounding obesity and obesity treatments.
- **Racism and discrimination:** There is no evidence to suggest that AB 575 would decrease racism and discrimination related to obesity diagnosis and treatment. Therefore, it is unlikely that AB 575 would reduce racial and ethnic disparities in obesity rates or treatment for obesity.
- **Location:** It is possible that people living in rural areas who are more likely to face challenges in accessing obesity treatments may benefit from AB 575 if an increase in coverage for weight management medications includes medications available via mail that could be sent to individuals living in more remote settings.
- **Expense:** The high cost of some obesity treatments make them inaccessible for insured patients with lower incomes (Levi et al., 2023). This may be especially true for expensive medications that require long-term use to address obesity. For individuals with health insurance subject to AB 575, FDA-approved medications for weight management could become more accessible due to the new insurance coverage requirements. Yet, because the cost sharing for some medications would be higher than for previously covered treatments, the benefits of the additional coverage from AB 575 may be seen predominantly by those insured with higher incomes who can afford to pay the cost-sharing for long term use.

Benefit Mandate Structure and Unequal Racial/Ethnic Health Impacts

AB 575 applies to the health insurance of enrollees in CDI-regulated policies and other enrollees in DMHC-regulated plans but would not be applicable to the health insurance of Medi-Cal beneficiaries enrolled in DMHC-regulated plans. As Medi-Cal beneficiaries already have coverage for the treatments included under AB 575 (i.e., GLP-1 medications with FDA indication for weight management and IBT for weight loss), the exclusion of Medi-Cal beneficiaries from AB 575 would not result in disparities in coverage for obesity treatments.

[Back to Table of Contents](#)

⁴⁸ For details about CHBRP's [methodological approach](#) to analyzing disparities, see the *Benefit Mandate Structure and Unequal Racial/Ethnic Health Impacts* document.

Long-Term Impacts

In this section, CHBRP estimates the long-term impact of AB 575, which CHBRP defines as impacts occurring beyond the first 12 months after implementation. These estimates are qualitative and based on the existing evidence available in the literature. CHBRP does not provide quantitative estimates of long-term impacts because of unknown improvements in clinical care, changes in prices, implementation of other complementary or conflicting policies, and other unexpected factors.

Long-Term Utilization and Cost Impacts

Utilization Impacts

CHBRP estimates that enrollees will use glucagon-like peptide-1 (GLP-1) medications to treat obesity due to AB 575. During Year 2, additional increases in use will have implications for increases in premiums.

There is little evidence that GLP-1 medications will reduce emergency room visits and hospitalizations for enrollees with obesity. Although GLP-1 use has been shown generate reduction in heart failure/heart attacks between 12 and 18 months of use, there is no current evidence on long-term benefits and reductions in avoidable care (Lincoff et al., 2023; Sattar et al., 2021). However, GLP-1s appear to hold promise in treating other conditions, including substance use disorders, that may have long-term effects. There are additional GLP-1 medications undergoing clinical trials (e.g., orforglipron), a daily oral medication for diabetes and obesity) that are likely to be approved in the coming years. AB 575 requires coverage of at least one GLP-1 AOM medication, and as new medications enter the market, they might be adopted more readily depending on the price point, side effects, and clinical effectiveness. Over time, generic GLP-1 alternatives could be used as substitutes for the current brand-name version of the medications. This substitution effect would put downward pressure on prices and therefore health insurance premiums related to that benefit, but it could also facilitate more widespread use of the medications as they become more affordable and accessible.

Cost Impacts

In Year 2, CHBRP estimates premiums would increase by over 1% in most market segments due to higher levels of coverage and subsequent use of GLP-1 medications.

Long-Term Public Health Impacts

Some interventions in proposed mandates provide immediate measurable impacts (e.g., maternity service coverage or acute care treatments), whereas other interventions may take years to make a measurable impact (e.g., coverage for tobacco cessation or vaccinations). When possible, CHBRP estimates the long-term effects (beyond 12 months postmandate) to the public's health that would be attributable to the mandate, including impacts disparities, premature death, and economic loss.

In the case of AB 575 CHBRP estimates approximately 182,520 enrollees would newly use treatments for obesity within 1-year postmandate. It is estimated that these individuals would lose between 5% and 21% of their body weight. Therefore, public health impacts would be likely to accrue to these individuals outside of the 1-year time frame as they continue to lose and maintain their weight loss. As reported in the *Medical Effectiveness* section, there was limited evidence to evaluate the long-term benefits of obesity treatments, particularly regarding persistent use of medication and sustained weight loss after discontinuation. For example, evidence suggests that individuals taking GLP-1 medications, have 1-year discontinuation rates between 46.5% and 64.8% which often leads to regaining lost weight (Rodriguez et al., 2025). Therefore, although this limited evidence suggests that we would continue to see a reduction in the overall prevalence of obesity and obesity-related chronic disease, including a reduction in cardiovascular disease, hypertension (i.e., high blood pressure), type 2 diabetes, and certain types of cancer, the magnitude of these benefits is unknown.

Impacts on Premature Death and Economic Loss

Premature death

Premature death, measured by years of potential life lost (YPLL), is often defined as death occurring before the age of 75 years (NCI, 2019).⁴⁹ Fontaine et al. (2003) found that the life expectancy for an adult with a class 3 obesity (i.e., BMI > 45) reduced by a range of 5 to 20 YPLL — depending on sex and race and ethnicity. Specifically, overweight men aged 20 to 39 years lost an estimated 2.7 years of life, whereas obese and severely obese (class 2 or class 3 obesity) men lost 5.9 and 8.4 years, respectively, compared to men with a healthy body weight (Grover et al., 2015). Additionally, obese women in the same age group experienced up to 6.1 years of life lost, with the highest impact seen in younger individuals. Increased body weight was also associated with a significant reduction in healthy life years, with young severely obese men losing 18.8 years and young severely obese women losing 19.1 years (Grover et al., 2015). According to the CDC Wonder online database, 881 adult deaths in California were directly attributed to obesity, equal to a rate of 3.0 per 100,000 persons, in 2023 (CDC, 2023a). Although AB 575 has the potential to impact premature death, the extent to which this may occur is unknown.

Economic loss

Economic loss associated with disease is generally presented in the literature as an estimation of the value of the YPLL in dollar amounts (i.e., valuation of a population's lost years of work over a lifetime). In addition, morbidity associated with the disease or condition of interest can also result in lost productivity by causing a worker to miss days of work due to illness or acting as a caregiver for someone else who is ill.

Cawley et al. (2021b) found that obesity increases job absenteeism (either due to injury or illness) by an average of 4.68 days per year per obese individual in California. In addition, they estimated that each additional unit of BMI increased the average number of days of work lost by 0.20 days per year. This translated into productivity losses ranging from \$1.1 billion to \$2.1 billion per year in California.⁵⁰ It is estimated that AB 575 would increase utilization of obesity treatments by 182,520 people per year. Assuming an average weight loss of 13% (i.e., the mid-point of the range of 5%-21%), this would translate into an approximate decrease in lost productivity of 80,000 days per year, or \$9.4 to \$18.9 million per year. These savings would grow over time as the cumulative pool of people who have lost weight using obesity treatments grows. Similarly, estimates across the United States have shown that a reduction in the average BMI by 5% could save nearly \$30 billion in 5 years, save more than \$150 billion in 10 years, and more than \$600 billion in 20 years (Wang et al., 2011).

[Back to Table of Contents](#)

⁴⁹ See CHBRP's website for more information about [CHBRP's public health methodology](#).

⁵⁰ Translated into 2025 dollars using <https://www.usinflationcalculator.com/>.

Appendix A. Text of Bill Analyzed

On March 10, 2025 the California Assembly Committee on Health requested that CHBRP analyze AB 575 as amended on March 12, 2025.

Below is the bill language, as it was amended on March 12, 2025.

AMENDED IN ASSEMBLY MARCH 12, 2025

CALIFORNIA LEGISLATURE— 2025–2026 REGULAR SESSION

ASSEMBLY BILL

NO. 575

Introduced by Assembly Member Arambula

February 12, 2025

An act to add Section 1374.6 to the Health and Safety Code, and to add Section 10123.62 to the Insurance Code, relating to health care coverage.

LEGISLATIVE COUNSEL'S DIGEST

AB 575, as introduced, Arambula. Obesity Prevention Treatment Parity Act.

Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act's requirements a crime. Existing law provides for the regulation of disability and health insurers by the Department of Insurance. Existing law sets forth specified coverage requirements for plan contracts and insurance policies.

This bill, the Obesity Prevention Treatment Parity Act, would require an individual or group health care service plan contract or health insurance policy that provides coverage for outpatient prescription drug benefits, as specified, and is issued, amended, or renewed on or after January 1, 2026, to include coverage for at least one *specified* anti-obesity medication and intensive behavioral therapy for the treatment of obesity without prior authorization. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

DIGEST KEY

Vote: majority Appropriation: no Fiscal Committee: yes Local Program: yes

BILL TEXT

THE PEOPLE OF THE STATE OF CALIFORNIA DO ENACT AS FOLLOWS:

SECTION 1. This act shall be called, and may be cited as, the Obesity Prevention Treatment Parity Act.

SEC. 2. The Legislature finds and declares all of the following:

- (a) Obesity is a serious chronic disease that is recognized as such by major medical organizations, including the American Medical Association since 2013, the American Association of Clinical Endocrinology, the American College of Cardiology, the Endocrine Society, the American Society for Reproductive Medicine, the Society for Cardiovascular Angiography and Interventions, the American Urological Association, and the American College of Surgeons.
- (b) Obesity is linked to more than 200 comorbid conditions.
- (c) Obesity is associated with an increased risk of 13 types of cancer.
- (d) From 2005 to 2014, most cancers associated with obesity and being overweight increased in the United States, while cancers associated with other factors decreased.
- (e) Obesity reduces a patient's overall survival rate and cancer-specific survival rate, as well as increases the risk of cancer recurrence.
- (f) Obesity is a complex chronic disease, one in which genetics, the environment, and biology all play important factors.
- (g) Obesity disproportionately affects communities of color, in part because of barriers to accessing affordable healthy food options and safe environments to live an active lifestyle.
- (h) In rural communities, Black and Latino populations have the highest rates of obesity.
- (i) Obesity is impacted by socioeconomic status.
- (j) Californians living below the poverty line are 1.5 times more likely to be obese.
- (k) Adults suffering from obesity have a 55-percent higher risk of developing depression over their lifetime.
- (l) Complications with obesity can lead to increased risk of chronic disease including hypertension, diabetes, cardiovascular diseases, or mortality.
- (m) Obesity accounts for 47 percent of the total cost of chronic diseases in the United States.
- (n) Obesity is a highly stigmatized disease.
- (o) Barriers to accessing obesity treatments include stigma, racism, and discrimination.

- (p) In California, one out of four adults are obese, and obesity-related costs are estimated to be \$15.2 billion annually.
- (q) The California Code of Regulations currently requires coverage of outpatient prescription drugs for the treatment of obesity, but only when a patient is diagnosed with “morbid obesity,” modernly referred to as “severe obesity.”
- (r) Chronic diseases without the stigma, racism, and discrimination of obesity do not require patients to reach the designation of “morbid” to be worthy of treatment options that include outpatient prescription drugs.
- (s) Recently, the United States Food and Drug Administration approved several glucagon-like peptide-1 receptor agonists (GLP-1RAs) for weight management.
- (t) Glucagon-like peptide-1 receptor agonists are medications that help lower blood sugar levels and promote weight loss. However, not all insurance companies provide coverage for GLP-1RA medications despite mounting evidence indicating that this class of medications is safe and effective.
- (u) The Obesity Prevention Treatment Parity Act would address health equity gaps and social determinants of health for Californians by ensuring the full range of treatment options are available to patients, without them having to reach a level of obesity considered “morbid.”

SEC. 3. Section 1374.6 is added to the Health and Safety Code, to read:

1374.6. (a) Notwithstanding any other law, a group or individual health care service plan contract that provides coverage for outpatient prescription drug benefits that is issued, amended, or renewed on or after January 1, 2026, shall include coverage, without prior authorization, for all of the following for the treatment of obesity:

(1) At least one FDA-approved ~~anti-obesity medication, including, but not limited to, glucagon-like peptide-1 receptor agonists (GLP-1RAs)~~ *glucagon-like peptide-1 receptor agonist (GLP-1RA) for the treatment or prevention of obesity.*

(2) Intensive behavioral therapy.

(b) This section does not prohibit a plan from applying utilization management to determine the medical necessity for the treatment of obesity under this section if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by a contract.

(c) Coverage criteria for FDA-approved anti-obesity medications shall not be more restrictive than the FDA-approved indications for those treatments.

(d) This section does not apply to a specialized health care service plan contract that covers only dental or vision benefits or a Medicare supplement contract.

(e) For purposes of this section, the following terms have the following meanings:

(1) “FDA-approved anti-obesity medication” means a medication approved by the United States Food and Drug Administration with an indication for chronic weight management in patients with obesity.

(2) “Glucagon-like peptide-1 receptor ~~agonists (GLP-1RAs)~~ *agonist (GLP-1RA)*” means *one of* a class of medications that helps lower blood sugar levels and promote weight loss.

SEC. 4. Section 10123.62 is added to the Insurance Code, to read:

10123.62. (a) Notwithstanding any other law, a group or individual health insurance policy that provides coverage for outpatient prescription drug benefits that is issued, amended, or renewed on or after January 1, 2026, shall include coverage, without prior authorization, for all of the following for the treatment of obesity:

(1) At least one FDA-approved ~~anti-obesity medication, including, but not limited to, glucagon-like peptide-1 receptor agonists (GLP-1RAs)~~ *glucagon-like peptide-1 receptor agonist (GLP-1RA) for the treatment or prevention of obesity.*

(2) Intensive behavioral therapy.

(b) This section does not prohibit an insurer from applying utilization management to determine the medical necessity for the treatment of obesity under this section if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by a contract.

(c) Coverage criteria for FDA-approved anti-obesity medications shall not be more restrictive than the FDA-approved indications for those treatments.

(d) This section does not apply to a specialized health insurance policy that covers only dental or vision benefits or a Medicare supplement contract.

(e) For purposes of this section, the following terms have the following meanings:

(1) “FDA-approved anti-obesity medication” means a medication approved by the United States Food and Drug Administration with an indication for chronic weight management in patients with obesity.

(2) “Glucagon-like peptide-1 receptor ~~agonists (GLP-1RAs)~~ *agonist (GLP-1RA)*” means *one of* a class of medications that helps lower blood sugar levels and promote weight loss.

SEC. 5. No reimbursement is required by this act pursuant to Section 6 of Article XIII B of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIII B of the California Constitution.

[Back to Table of Contents](#)

Appendix B. Utilization Management

Utilization Management

Utilization management techniques are used by health plans and insurers to control costs, ensure medication compatibility, and manage safety. Examples include benefit coverage requirements related to prior authorization, step therapy, quantity limits, and limits related to the age or sex of the enrollee (such as prescription-only infant formula or prostate cancer screening for men). A brief description of some key utilization management techniques follows.

Prior authorization

Prior authorization⁵¹ – also known as precertification, prior approval, or prospective review – is a utilization management technique commonly used by health insurance carriers to ensure that a given medical intervention meets the insurance plan or policy’s criteria for coverage (Newcomer et al., 2017). Prior authorization developed as a tool for insurers to assess the appropriateness of treatment that would result in a hospital admission or a high-cost procedure (Resneck, 2020). The process typically requires providers to establish eligibility and submit documentation demonstrating medical need to the plan/insurer for approval of coverage before either medical services are provided or a prescription is filled in order to qualify for payment. Health plans/insurers may also impose prior authorization requirements on nonpreferred medications in an effort to promote the use of preferred medications that they can procure at lower prices.

The primary uses of prior authorization are as follows:

- **Coverage evaluation:** Allows evaluation of whether a test, treatment, or service is medically necessary and otherwise covered.
- **Safety:** Acts as a safeguard to confirm that a patient’s medications are compatible and provides an opportunity to check that proper diagnostic testing has been completed to ensure patient safety prior to use of a requested treatment. Prior authorization also reduces inappropriate patient care by stopping unsafe or low-value care that is inconsistent with the most recent clinical evidence.
- **Cost control:** Imposition of prior authorization for nonpreferred medications can encourage the use of preferred medications that can be procured at lower price.

Step therapy

Step therapy or “fail-first” protocols may be applied to prescription medications by health plans and insurers to control costs, ensure medication compatibility, and manage safety. Health plans/insurers may use step therapy protocols to apply clinical guidelines established by professional societies and other recognized organizations to treatment plans. They require an enrollee to try and fail one or more medications prior to receiving coverage for the initially prescribed medication. Step therapy protocols usually recommend starting with a medication that is less expensive (generics) and/or has more “post-marketing safety experience” (PBMI, 2015). In addition, they sometimes require starting with a less potent medication or dosage, perhaps with fewer side effects, and graduating to more potent medications as necessary (e.g., from prescription ibuprofen to oxycodone to treat pain). Generally, more expensive or more potent medications are covered when the patient fails to respond to the step therapy–required medication (PBMI, 2018).

[Back to Table of Contents](#)

⁵¹ More information about prior authorization is available in CHBRP’s 2023 [analysis](#), *Prior Authorization in California*.

Appendix C. Detailed Medical Effectiveness Study Findings for FDA-Approved GLP-1 AOMs

Study	Study Design and Size	Comorbidity (if Any)	Intervention	Findings
Liraglutide 3.0 mg (Saxenda) for adults with overweight or obesity				
Gudbergesen et al. (2021)	RCT (n = 156)	Symptomatic knee osteoarthritis	Liraglutide vs. placebo	Significantly greater reductions in BW and WC with liraglutide at 52 weeks. Significantly higher proportion of liraglutide participants with ≥5% weight loss.
Atlas et al. (2022) (a)	Evidence review of six RCTs (n = 5,825)	With and without diabetes	Liraglutide plus lifestyle intervention or IBT vs. placebo plus lifestyle intervention or IBT	Greater percent BW loss with liraglutide treatment ranging between 32-56 weeks. Higher proportions of liraglutide participants with ≥5% and ≥10% weight loss.
Shi et al. (2024) (b)	Systematic review and meta-analysis	—	Liraglutide plus lifestyle modification vs. lifestyle modification alone	Significantly greater percent BW loss with liraglutide. Significantly higher proportions of liraglutide participants with ≥5% and ≥10% weight loss.
Liraglutide 3.0 mg (Saxenda) for children and adolescents with overweight or obesity				
Cornejo-Estrada et al. (2023)	Meta-analysis of two RCTs (n = 272; aged 5 to 18 years)	—	Liraglutide vs. placebo	No statistically significant between group differences in BW loss or BMI reduction.
Semaglutide 2.4 mg (Wegovy) for adults with overweight or obesity				
Davies et al. (2021)	RCT (n = 1,210)	Type 2 diabetes	Semaglutide plus lifestyle intervention vs. placebo plus lifestyle intervention	Significantly greater reductions in BW and WC with semaglutide at 68 weeks. Significantly higher proportions of semaglutide participants with ≥5%, ≥10%, and ≥15% weight loss.
Lincoff et al. (2023)	RCT (n = 17,604)	Pre-existing cardiovascular disease but no diabetes	Semaglutide vs. placebo	Significantly greater reductions in percent BW and WC with semaglutide at 104 weeks.

Study	Study Design and Size	Comorbidity (if Any)	Intervention	Findings
Qin et al. (2024) (c)	Systematic review and meta-analysis of six RCTs (n = 3,962)	No diabetes	Semaglutide vs. placebo	Significantly greater reductions in percent BW, absolute BW, BMI, and WC with semaglutide treatment ranging between 20 to 104 weeks. Significantly higher proportions of semaglutide participants with $\geq 5\%$, $\geq 10\%$, $\geq 15\%$, and $\geq 20\%$ weight loss.
Kosiborod et al. (2024)	RCT (n = 616)	Obesity-related heart failure and type 2 diabetes	Semaglutide plus baseline glucose-lowering medication vs. placebo plus baseline glucose-lowering medication	Significantly greater reductions in percent BW with semaglutide at 52 weeks.
McGowan et al. (2024)	RCT (n = 207)	Prediabetes	Semaglutide plus lifestyle intervention vs. placebo plus lifestyle intervention	Significantly greater reductions in percent BW and WC with semaglutide at 52 weeks. Significantly higher proportions of semaglutide participants with $\geq 5\%$, $\geq 10\%$, $\geq 15\%$, and $\geq 20\%$ weight loss.
Shi et al. (2024)	Systematic review and meta-analysis	-	Semaglutide plus lifestyle modification vs. lifestyle modification alone	Significantly greater percent BW loss with semaglutide. Higher proportions of semaglutide participants with $\geq 5\%$ and $\geq 10\%$ weight loss.
Semaglutide 2.4 mg (Wegovy) for children and adolescents with overweight or obesity				
Weghuber et al. (2022)	RCT (n = 201; aged 12 to 18 years)	At least one weight-related coexisting condition if overweight	Semaglutide plus lifestyle modification vs. placebo plus lifestyle modification	Significantly greater BMI reduction with semaglutide at 68 weeks. Significantly higher proportions of semaglutide participants with $\geq 5\%$ weight loss.
Kelly et al. (2023)	Post hoc analysis of Weghuber et al. (2022) RCT	At least one weight-related coexisting condition if overweight	Semaglutide plus lifestyle modification vs. placebo plus lifestyle modification	Significantly higher likelihood of being reclassified to a normal-weight or overweight BMI category with semaglutide. Significantly greater odds of achieving an improvement of at least one BMI category with semaglutide.
Tirzepatide (Zepbound) for adults with overweight or obesity				

Study	Study Design and Size	Comorbidity (if Any)	Intervention	Findings
Jastreboff et al. (2022)	RCT (n = 2,539)	No diabetes, and at least one weight-related coexisting condition if overweight	Tirzepatide (5 mg, 10 mg, and 15 mg) plus lifestyle counseling vs. placebo plus lifestyle counseling	Significantly greater reductions in percent BW with tirzepatide at 72 weeks. Significantly greater proportions of participants with $\geq 5\%$ weight loss for all tirzepatide doses. Significantly greater proportions of participants with $\geq 20\%$ weight loss with 10 mg and 15 mg doses compared to placebo.
Liu et al. (2024)	Systematic review and meta-analysis of three RCTs (n = 3,901)	No diabetes	Tirzepatide (5 mg, 10 mg, and 15 mg) plus lifestyle interventions vs. placebo plus lifestyle interventions	Significantly greater reductions in percent BW, BMI, and WC with tirzepatide for 72 or 88 weeks. Significantly higher proportions of tirzepatide participants with $\geq 5\%$, $\geq 10\%$, $\geq 15\%$, $\geq 20\%$, and $\geq 25\%$ weight loss.
Tirzepatide (Zepbound) is not approved for use in children and adolescents				

Source: California Health Benefits Review Program, 2025.

Note: (a) The Institute for Clinical and Economic Review (ICER) report by Atlas et al. (2022) presents findings from a systematic review and meta-analysis of 37 studies of two GLP-1 medications approved by the FDA for chronic weight management: liraglutide 3.0 mg and semaglutide 2.4 mg. Most of the evidence regarding the effectiveness of these medications comes from Phase III RCTs conducted prior to FDA approval. These RCTs compared the AOMs to placebo among patients who received a variety of lifestyle interventions (e.g., reduced-calorie diet, increased physical activity), and to placebo among patients who received IBT. As a result, the studies assessed the additive benefit of the medications in addition to supplemental interventions. Findings on semaglutide from the ICER report are not included in this report because a newer systematic review and meta-analysis of the same studies plus an additional RCT was conducted by Qin et al. in 2024.

(b) The systematic review and meta-analysis by Shi et al. (2024) compared different AOMs (including liraglutide 3.0 mg, semaglutide 2.4 mg) plus lifestyle modification with lifestyle modification alone with or without placebo or an alternative active drug across 132 RCTs involving 48,209 adult participants with overweight or obesity. The follow-up duration of these studies was at least 1 year.

(c) Four of the RCTs employed a lifestyle intervention in addition to both semaglutide and placebo treatments, one RCT employed a low-calorie diet plus IBT, and one RCT did not mention employing any supplemental interventions.

Key: BMI = body mass index; BW = body weight; CHBRP = California Health Benefits Review Program; GLP-1 = glucagon-like peptide-1; WC = waist circumference.

Appendix D. Cost Impact Analysis: Data Sources, Caveats, and Assumptions

With the assistance of CHBRP's contracted actuarial firm, Milliman, Inc., the cost analysis presented in this report was prepared by the faculty and researchers connected to CHBRP's Task Force with expertise in health economics.⁵² Information on the generally used data sources and estimation methods, as well as caveats and assumptions generally applicable to CHBRP's cost impacts analyses, are available on CHBRP's website.⁵³

This appendix describes analysis-specific data sources, estimation methods, caveats, and assumptions used in preparing this cost impact analysis.

Analysis-Specific Data Sources

Baseline coverage of obesity for commercial enrollees was determined by a survey of the largest (by enrollment) providers of health insurance in California. Responses to this survey represented 86% of commercial enrollees with health insurance that can be subject to state benefit mandates. In addition, CalPERS and DHCS were queried regarding related benefit coverage.

Health Cost Guidelines

Milliman's Health Cost Guidelines (HCGs) are a health care pricing tool used by actuaries in many of the major health plans in the United States. The guidelines provide a flexible but consistent basis for estimating health care costs for a wide variety of commercial health insurance plans. It is likely that these organizations use the HCGs, among other tools, to determine the initial premium impact of any new mandate. Thus, in addition to producing accurate estimates of the costs of a mandate, we believe the HCG-based values are also good estimates of the premium impact as estimated by the HMOs and insurance companies.

The highlights of the commercial HCGs include:

- Specific major medical, managed care, and prescription drug rating sections and guidance with step-by-step rating instructions.
- Other helpful analysis resources, such as inpatient length of stay distribution tables, Medicare Severity-Adjusted Diagnosis Related Group (MS-DRG) models, and supplementary sections addressing EHBs and mandated benefits, experience rating, and individual and small group rating considerations.
- Presentation of loosely and well-managed nationwide utilization and cost information by Milliman benefit-aligned service categories used throughout the Rating Structures – inpatient hospital services for both loosely and well-managed are also supported by DRG level utilization and cost benchmarks.
- Annual updates address emerging regulatory considerations such as health care reform and mental health parity requirements.
- Annually updated benefit descriptions used in the HCG service categories.
- Annually updated medical trend assumptions and considerations.
- Presentation of two sets of nationwide area factors to facilitate development of area-specific claim costs, including separate utilization and charge level factors by type of benefit, state and Metropolitan Statistical Area for first-dollar coverage, and composite factors by deductible amount.
- Claim Probability Distributions (CPDs) by type of coverage that contain distributions of claim severity patterns for unique combinations of benefits and member types (adult, child, composite member).

⁵² CHBRP's [authorizing statute](#) requires that CHBRP use a certified actuary or "other person with relevant knowledge and expertise" to determine financial impact.

⁵³ See [CHBRP's Cost Impact Analysis landing page](#); in particular, see *Cost Impact Analyses: Data Sources, Caveats, and Assumptions*.

The Prescription Drug Rating Model (RXRM), an automated rating tool that provides a detailed analysis of prescription drug costs and benefits.

Consolidated Health Cost Guidelines Sources Database

Milliman maintains benchmarking and analytic databases that include health care claims data for nearly 60 million commercial lives and over 3 million lives of Medicaid managed care data. This dataset is routinely used to evaluate program impacts on cost and other outcomes.

Detailed Cost Notes Regarding Analysis-Specific Caveats and Assumptions

The analytic approach and key assumptions are determined by the subject matter and language of the bill being analyzed by CHBRP. As a result, analytic approaches may differ between topically similar analyses, and therefore the approach and findings may not be directly comparable. Prior CHBRP analyses of obesity treatment bills included changes in cost sharing parity and differences in prescription drug coverage. The analysis of AB 575 focuses on changes in cost due to changes in coverage only and does not assume that all plans will cover other non-GLP-1 anti-obesity medications. The methodology and results of AB 575 cost analysis are not comparable to results of prior obesity bills. The results of this analysis may be sensitive to the behavior of plan sponsors in response to the mandate, such as utilization management of GLP-1s.

For this analysis, CHBRP relied on CPT codes to identify services related to AB 575. CPT copyright 2023 American Medical Association. All rights reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association.

Methodology and Assumptions for Baseline Benefit Coverage

The population subject to the mandated offering includes individuals covered by DMHC-regulated commercial insurance plans, CDI-regulated policies, and CalPERS plans subject to the requirements of the Knox-Keene Health Care Service Plan Act.

- DMHC-regulated Medi-Cal plans are exempt from this mandate.
- CHBRP conducted a survey of the largest (by enrollment) providers of health insurance in California to determine the percentage of enrollees that have pharmacy coverage.
- CHBRP conducted a survey of the largest (by enrollment) providers of health insurance in California to determine the percentage of the population subject to the mandate who currently receive coverage as mandated by AB 575.
- CHBRP separately polled coverage for obesity treatments.
- Responses to the survey of providers of health insurance represent 75% of commercial enrollees with health insurance that can be subject to state benefit mandates. For those providers who did not respond, CHBRP used survey responses from the SB 839 cost analysis.

CHBRP assumes that CalPERS does not currently cover GLP-1s for weight loss across all segments based on a review of CalPERS' online formulary as of April 17, 2025. CHBRP assumes that CalPERS covers intensive behavioral therapy (IBT).

CHBRP conducted a carrier survey to determine the percentage of enrollees that are enrolled in plans by regulator, line of business, and deductible or metal tier.

Analysis Specific Data Sources

Glucagon-Like Peptide-1 Receptor Agonist Anti-Obesity Medication

CHBRP identified SAXENDA, WEGOVY, and ZEPBOUND as the glucagon-like peptide-1 receptor agonist (GLP-1) medications for weight loss which may be covered under AB 575.

CHBRP's typical data source does not contain information related to whether these medications are on a health plan's formulary. Therefore, the data used for this analysis is 2024 pharmacy claims data from Milliman's MyRxConsultant for a national self-insured employer that offers coverage these medications and has offered such coverage for several years. CHBRP used this data source as an estimate for unit cost and to set assumptions on baseline utilization:

- Estimated unit cost is consistent with a 30-day supply. Estimated unit cost is based upon pricing of direct-to-consumer programs for WEGOVY and ZEPBOUND offered by manufacturers. While these programs are not available through insurance, CHBRP assumes the insurers' negotiated net cost would be similar. Therefore, we estimated that the unit cost for GLP-1s would be \$499 monthly.
- Estimated unit cost reflects pricing concessions from manufacturer rebates.
- CHBRP estimated that 7.5% of enrollees with obesity and full coverage by their health plan would use these medications in year 1 and 11.3% in year 2.
- CHBRP estimates that 1.8% of individuals without coverage would self-pay for these medications premandate. This information is based upon CHBRP's interpretation of the KFF Survey.
- Estimated utilization is consistent with high observed trends for these medications and an assumption that supply chain issues are and remain fully resolved at baseline.

Intensive Behavioral Therapy

Utilization is based upon commercially insured enrollees in California during 2023 from Milliman's Consolidated Health Research Databases, with an assumption that 50% of IBT is reimbursed outside claims systems. To identify the number of enrollees within the database that utilized IBT services we took the following approach.

- CHBRP assumed that the following ICD10 diagnosis codes indicate obesity for the purposes of identifying relevant IBT: E66.0, E66.01, E66.09, E66.1, E66.2, E66.8, and E66.9.
- CHBRP assumed that services for the following CPT codes are specific to weight loss and obesity if the enrollee had a diagnosis for obesity during the year. These CPT codes include 97802, 97803, 97804, G0270, G0271, G0446, G0447, and G0473.
- CHBRP assumed that services for the following CPT codes are specific to weight loss and obesity if the same medical claim indicated a diagnosis for obesity. These CPT codes include 99078, 99080, 99401, and 99402.
- Finally, the number of enrollees was increased by a factor of two to account for the assumption that 50% of IBT is reimbursed outside claims systems.
- Unit cost is based upon publicly available information from the CDC, estimating that the cost per enrollee per year of a Diabetes Prevention Program (DPP) is \$500. Note that DPP is the "gold standard" of IBT.⁵⁴

⁵⁴ Personal communication with content expert D. Thiara, MD. March 2025.

Methodology and Assumptions for Baseline Utilization and Cost

Baseline utilization is driven primarily based upon whether enrollees have coverage at baseline and CHBRP's analysis of claims data for enrollees who have full coverage at baseline. More information for each treatment is found above.

Table 12. Baseline Utilization of Obesity Treatments

	GLP-1s (Year 1)	GLP-1s (Year 2)	IBT (Year 1)	IBT (Year 2)
Enrollees with full coverage	7.5%	11.3%	0.5%	0.5%
Enrollees without coverage at baseline	1.8%	2.6%	0.0%	0.0%

Source: California Health Benefits Review Program, 2025.

Note: Table represents percentage of obese enrollees utilizing services at baseline.

Key: GLP = glucagon-like peptide; IBT = intensive behavioral therapy.

By market segment, utilization varies by the estimated prevalence of obesity. CHBRP's Cost model uses assumptions consistent with the prevalence of obesity discussed in the Public Health section. Based on the results of Milliman's Commercial Drug Trend Study⁵⁵ and Health Cost Guidelines, CHBRP assumed a 50% utilization trend for GLP-1s. CHBRP assumed no trend for IBT.

CHBRP assumed that self-pay utilization is 0% for IBT. In practice, some enrollees pay directly for the IBT program of their choice. However, relating to IBT, all carriers cover some form of these services.

Methodology and Assumptions for Baseline Cost Sharing

- CHBRP assumed that cost sharing would be similar to average cost sharing (or average coinsurance) for a typical plan design within each metal level or deductible level.
- CHBRP assumed that cost sharing for IBT was \$0 if indicated in the carrier survey at baseline.

Methodology and Assumptions for Postmandate Utilization

CHBRP conducted a carrier survey to determine the percentage of enrollees with fully compliant coverage at baseline. The survey was specific to each treatment.

Postmandate utilization is consistent with full coverage. In particular, CHBRP assumed that health plans without an outpatient prescription drug benefit would be required to cover medications for weight loss.

Methodology and Assumptions for Postmandate Cost

CHBRP assumed the average cost per service would not change as a result of AB 575.

⁵⁵ Milliman's Commercial Drug Trends reports for 2023 and 2024 showed that utilization of GLP-1 medications increased by over 40% from 2021 to 2022, and more than doubled between 2022 and 2023.

Methodology and Assumptions for Postmandate Cost Sharing

Postmandate, CHBRP assumed that all services are fully covered. CHBRP assumed that cost sharing would be similar to average cost sharing (or average coinsurance) for a typical plan design within each metal level or deductible level.

CHBRP assumed that cost sharing for IBT was \$0 if indicated in the carrier survey at baseline.

Methodology and Assumptions for Year 2 Offsets

CHBRP assumed that medical costs in year 2 will be reduced by \$100 per GLP-1 user per year.

Second-Year Benefit Coverage

Below, Table 13 provides estimates of how many Californians have health insurance that would have to comply with AB 575 in terms of benefit coverage during 2027.

Table 13. AB 575 Impacts on Benefit Coverage, 2027

	Baseline (2027)	Postmandate Year 2 (2027)	Increase/Decrease	Change Postmandate
Total enrollees with health insurance subject to state benefit mandates*	22,239,000	22,239,000	0	0.00%
Total enrollees with health insurance subject to AB 575	13,589,000	13,589,000	0	0.00%
Enrollees with coverage for GLP-1 AOMs				
Percentage of enrollees with coverage for GLP-1 medications	17.4%	100.0%	82.6%	475.35%
Percentage of enrollees without coverage for GLP-1 medications	82.6%	0.0%	-82.6%	-100.00%
Enrollees with coverage for IBT				
Percentage of enrollees with coverage for IBT	99.8%	100.0%	0.2%	0.22%
Percentage of enrollees without coverage for IBT	0.2%	0.0%	-0.2%	-100.00%

Source: California Health Benefits Review Program, 2025.

Notes: * Enrollees in plans and policies regulated by DMHC or CDI. Includes those associated with Covered California, CalPERS, or Medi-Cal.⁵⁶

Key: AOM = anti-obesity medication; CalPERS = California Public Employees' Retirement System; CDI = California Department of Insurance; DMHC = Department of Managed Health Care; GLP-1 = glucagon-like peptide-1; IBT = intensive behavioral therapy.

⁵⁶ For more detail, see CHBRP's [resource](#), *Sources of Health Insurance in California*.

Second-Year Utilization and Cost

Below, **Error! Reference source not found.** provides second-year estimates of the impacts of AB 575 on utilization and unit cost of IBT and FDA-approved GLP-1 AOMs.

Table 14. AB 575 Impacts on Utilization and Unit Cost, 2027

	Baseline (2027)	Postmandate Year 2 (2027)	Increase/ Decrease	Change Postmandate
Eligible populations				
Number of enrollees with obesity	3,069,534	3,069,534	—	0.00%
Number of overweight enrollees with comorbidities	757,466	757,466	—	0.00%
Utilization without coverage				
Number of enrollees using GLP-1 AOM	64,290	—	(64,290)	–100.00%
Number of enrollees receiving IBT	—	—	—	0.00%
Utilization with coverage				
Number of enrollees using GLP-1 AOM	56,621	330,699	274,078	484.06%
Number of enrollees receiving IBT	16,304	16,340	36	0.22%
Average unit cost				
Average unit cost of GLP-1 AOM	\$499	\$499	\$0	0%
Average unit cost of IBT	\$500	\$500	\$0	0%
Average cost sharing				
Average cost sharing for GLP-1 AOM	\$57.78	\$67.53	\$9.75	16.88%
Average cost sharing for IBT	\$2.08	\$2.23	\$0.15	7.46%

Source: California Health Benefits Review Program, 2025.

Key: AOM = anti-obesity medication; GLP-1 = glucagon-like peptide-1; IBT = intensive behavioral therapy.

Second-Year Expenditures

Table 15 provides second-year estimates of the impacts of AB 575 on expenditures, which include premiums, enrollee cost sharing, and enrollee expenses for noncovered benefits. For DMHC-regulated plans and CDI-regulated policies, AB 575 would increase total premiums paid by employers and enrollees for newly covered benefits. Enrollee expenses noncovered benefits would decrease, however cost sharing would increase. Overall, second-year expenditures would be anticipated to be higher than first-year expenditures.

Table 15. AB 575 Impacts on Expenditures, 2027

	Baseline (2027)	Postmandate Year 2 (2027)	Increase/ Decrease	Percentage Change
Premiums				
Employer-sponsored (a)	\$73,833,306,000	\$74,708,255,000	\$874,949,000	1.19%
CalPERS employer (b)	\$8,522,707,000	\$8,614,723,000	\$92,016,000	1.08%
Medi-Cal (excludes COHS) (c)	\$32,904,356,000	\$32,904,356,000	\$0	0.00%
Enrollee premiums (expenditures)				
Enrollees, individually purchased insurance	\$23,617,760,000	\$23,886,641,000	\$268,881,000	1.14%
Outside Covered California	\$6,530,812,000	\$6,593,280,000	\$62,468,000	0.96%
Through Covered California	\$17,086,948,000	\$17,293,361,000	\$206,413,000	1.21%
Enrollees, group insurance (d)	\$23,328,885,000	\$23,602,914,000	\$274,029,000	1.17%
Enrollee out-of-pocket expenses				
Cost-sharing for covered benefits (deductibles, copayments, etc.)	\$20,485,892,000	\$20,711,783,000	\$225,891,000	1.10%
Expenses for noncovered benefits (e) (f)	\$384,968,000	\$0	-\$384,968,000	-100.00%
Total expenditures	\$183,077,874,000	\$184,428,672,000	\$1,350,798,000	0.74%

Source: California Health Benefits Review Program, 2025.

Notes: (a) In some cases, a union or other organization. Excludes CalPERS.

(b) Includes only CalPERS enrollees in DMHC-regulated plans. Approximately 54.0% are state retirees, state employees, or their dependents. About one in five (20.5%) of these enrollees has a pharmacy benefit not subject to DMHC. CHBRP has projected no impact for those enrollees. However, CalPERS could, postmandate, require equivalent coverage for all its members (which could increase the total impact on CalPERS).

(c) Includes only Medi-Cal beneficiaries enrolled in DMHC-regulated plans. In addition, CHBRP is estimating it seems likely that there would also be a proportional increase of \$0 million for Medi-Cal beneficiaries enrolled in COHS managed care.

(d) Enrollee premium expenditures include contributions by enrollees to employer (or union or other organization)-sponsored health insurance, health insurance purchased through Covered California, and any contributions to enrollment through Medi-Cal to a DMHC-regulated plan.

(e) Includes only expenses paid directly by enrollees (or other sources) to providers for services related to the mandated benefit that are not covered by insurance at baseline. This only includes those expenses that will be newly covered postmandate. Other components of expenditures in this table include all health care services covered by insurance.

(f) For covered benefits, such expenses would be eliminated, although enrollees with newly compliant benefit coverage might pay some expenses if benefit coverage is denied (through utilization management review).

Key: CalPERS = California Public Employees' Retirement System; CDI = California Department of Insurance; COHS = County Organized Health Systems; DMHC = Department of Managed Health Care.

[Back to Table of Contents](#)

References

- Aaseth J, Ellefsen S, Alehagen U, Sundfør TM, Alexander J. Diets and drugs for weight loss and health in obesity — an update. *Biomedicine & Pharmacotherapy*. 2021;140:111789. doi:10.1016/j.biopha.2021.111789
- Aboueid S, Bourgeault I, Giroux I. Nutrition care practices of primary care providers for weight management in multidisciplinary primary care settings in Ontario, Canada - A qualitative study. *BMC Family Practice*. 2018;19(1):69. doi:10.1186/s12875-018-0760-3
- Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. *Advances in Therapy*. 2021;38(6):2821–2839. doi:10.1007/s12325-021-01710-0
- Atlas SJ, Kim K, Beinfeld M, et al. Medications for Obesity Management: Effectiveness and Value; Final Evidence Report. Institute for Clinical and Economic Review. October 20, 2022. Available at: <https://icer.org/assessment/obesity-management-2022/>. Accessed March 2025.
- Cawley J, Biener A, Meyerhoefer C, Ding Y, Zvenych T, Smolarz BG, Ramasamy A. Direct medical costs of obesity in the United States and the most populous states. *Journal of Managed Care & Specialty Pharmacy*. 2021a;27(3):354-366. doi:10.18553/jmcp.2021.20410
- Cawley J, Biener A, Meyerhoefer C, Ding Y, Zvenych T, Smolarz BG, Ramasamy A. Job absenteeism costs of obesity in the United States: National and state-level estimates. *Journal of Occupational and Environmental Medicine*. 2021b;63(7):565-573. doi:10.1097/JOM.0000000000002198
- Centers for Disease Control and Prevention (CDC). About Underlying Cause of Death, 2018-2023, Single Race. CDC Wonder. 2023a. Available at: <http://wonder.cdc.gov/ucd-icd10-expanded.html>. Accessed March 17, 2025.
- Centers for Disease Control and Prevention (CDC). Adult BMI Categories. March 19, 2024a. Available at: <https://www.cdc.gov/bmi/adult-calculator/bmi-categories.html>. Accessed March 2025.
- Centers for Disease Control and Prevention (CDC). Child and Teen BMI Categories. June 28, 2024b. Available at: <https://www.cdc.gov/bmi/child-teen-calculator/bmi-categories.html>. Accessed March 2025.
- Centers for Disease Control and Prevention (CDC). High Obesity Program. Last updated January 13, 2025. Available at: <https://www.cdc.gov/hop/php/about/index.html>. Accessed on March 11, 2025.
- Centers for Disease Control and Prevention (CDC). National Diabetes Prevention Program. 2023b. Available at: <https://www.cdc.gov/diabetes/prevention/find-a-program.html>. Accessed March 2025.
- Centers for Disease Control and Prevention (CDC). Risk Factors for Obesity. March 18, 2024c. Available at: <https://www.cdc.gov/obesity/risk-factors/risk-factors.html>. Accessed March 2025.
- Centers for Disease Control and Prevention (CDC). State Physical Activity and Nutrition. Last updated November 13, 2024d. Available at: <https://www.cdc.gov/span/php/about/index.html>. Accessed on March 11, 2025.
- Centers for Medicare & Medicaid Services (CMS). Medicaid Drug Rebate Program (MDRP). Last updated February 21, 2025a. Available at: <https://www.medicare.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html>. Accessed on March 11, 2025.
- Centers for Medicare & Medicaid Services (CMS). Medicaid Can Cover Obesity-Related Services, Helping Beneficiaries Reduce the Risk of Chronic Disease. 2025b. Available at: <https://www.medicare.gov/about-us/program-history/medicaid-50th-anniversary/entry/47693>. Accessed on March 11, 2025.
- Ciardullo S, Morieri ML, Daniel G, et al. GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes. *Acta Diabetologica*. 2024;61(8):941-950. <https://doi.org/10.1007/s00592-024-02300-6>
- Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. In: *StatPearls*. Treasure Island, FL: StatPearls Publishing; February 29, 2024.

- Cornier MA. A review of current guidelines for the treatment of obesity. *American Journal of Managed Care*. 2022;28(15 Suppl):S288-S296. doi:10.37765/ajmc.2022.89292
- Cornejo-Estrada A, Nieto-Rodríguez C, León-Figueroa DA, Moreno-Ramos E, Cabanillas-Ramirez C, Barboza JJ. Efficacy of liraglutide in obesity in children and adolescents: systematic review and meta-analysis of randomized controlled trials. *Children (Basel, Switzerland)*. 2023;10(2):208. doi:10.3390/children10020208
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *Lancet*. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0.
- Eyth E, Naik R. Hemoglobin A1C. In: *StatPearls*. Treasure Island, FL: StatPearls Publishing; March 13, 2023.
- Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. *JAMA*. 2003;289(2):187-193. doi:10.1001/jama.289.2.187
- Gasoyan H, Pfoh ER, Schulte R, Sullivan E, Le P, Rothberg MB. Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills. *Diabetes, Obesity & Metabolism*. 2024;26(5):1687-1696. doi: 10.1111/dom.15473
- Grover SA, Kaouache M, Rempel P, et al. Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study. *Lancet Diabetes & Endocrinology*. 2015 Feb;3(2):114-22. doi:10.1016/S2213-8587(14)70229-3
- Grunvald E, Shah R, Hernaez R, et al., AGA Clinical Guidelines Committee. AGA clinical practice guideline on pharmacological interventions for adults with obesity. *Gastroenterology*. 2022;163(5):1198-225. doi:10.1053/j.gastro.2022.08.045
- Gudbergson H, Overgaard A, Henriksen M, et al. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. *American Journal of Clinical Nutrition*. 2021;113(2):314-323. doi:10.1093/ajcn/nqaa328
- Hampel SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. *Pediatrics*. 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640
- Hersch DE, Uy MJ, Ngaw SM, Loth KA. Primary care providers' perspectives on initiating childhood obesity conversations: A qualitative study. *Family Practice*. 2021;38(4):460-467. doi:10.1093/fampra/cmab144
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. *New England Journal of Medicine*. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
- Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Journal of the American College of Cardiology*, 2014;63(25 Part B):2985-3023. <https://doi.org/10.1016/j.jacc.2013.11.004>
- Jobanputra R, Sargeant JA, Almaqhawi A, et al. The effects of weight-lowering pharmacotherapies on physical activity, function and fitness: a systematic review and meta-analysis of randomized controlled trials. *Obesity Reviews*. 2023;24(4):e13553. doi:10.1111/obr.13553
- Jung MH, Ihm S-H. Obesity-related hypertension and chronic kidney disease: from evaluation to management. *Kidney Research and Clinical Practice*. 2023;42(4):431-444. doi:10.23876/j.krmp.23.072
- Kelly AS, Arslanian S, Hesse D, et al. Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg. *Obesity (Silver Spring)*. 2023;31(8):2139-2149. doi:10.1002/oby.23808
- Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. *New England Journal of Medicine*. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963
- LeBlanc EL, Patnode CD, Webber EM, Redmond N, Rushkin M, O'Connor EA. *Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S.*

Preventive Services Task Force. Evidence Synthesis, No. 168. Rockville, MD: Agency for Healthcare Research and Quality; 2018. (Available at: <https://www.ncbi.nlm.nih.gov/books/NBK532379/>. Accessed March 17, 2025.

Levi J, Wang J, Venter F, Hill A. Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. *Obesity*. 2023;31(5):1270-1279. doi:10.1002/oby.23725

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *New England Journal of Medicine*. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563

Liu L, Shi H, Xie M, Sun Y, Nahata MC. Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials. *International Journal of Clinical Pharmacy*. 2024;46(6):1268-1280. doi:10.1007/s11096-024-01779-x

Lu Y, Liu Y, Krumholz HM. Racial and ethnic disparities in financial barriers among overweight and obese adults eligible for semaglutide in the United States. *Journal of the American Heart Association*. 2022;11(19):e025545. doi:10.1161/JAHA.121.025545

McGough M, Lo J, Tevis D, Rae M, Cox C. How Many Adults With Private Health Insurance Could Use GLP-1 Drugs? Peterson-KFF Health System Tracker. September 5, 2024. Available at: <https://www.healthsystemtracker.org/brief/how-many-adults-with-private-health-insurance-could-use-glp-1-drugs>. Accessed March, 2025.

McGowan BM, Bruun JM, Capehorn M, et al. Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. *Lancet Diabetes & Endocrinology*. 2024;12(9):631-642. doi:10.1016/S2213-8587(24)00182-7

Mekonnen A, Vasilevski V, Chapman A, Naughton S, Yuen E, Willcox J, et al. Barriers and enablers to effective weight management for people living with overweight and obesity: a rapid scoping review. *Obesity Reviews*. 2024;26(3):e13858. doi:10.1111/obr.13858

Montero A, Sparks G, Presiado M, Hamel L. KFF Health Tracking Poll May 2024: The Public's Use and Views of GLP-1 Drugs. May 10, 2024. Available at: <https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/>. Accessed March, 2025.

National Cancer Institute (NCI). NCI Dictionary of Cancer Terms: Premature Death. 2019. Available at: www.cancer.gov/publications/dictionaries/cancer-terms/def/premature-death. Accessed March 2025.

National Conference of State Legislators (NCSL). 'Compounded' Weight-Loss Drugs Are a Growing Problem for State Regulators. July 15, 2024. Available at: <https://www.ncsl.org/state-legislatures-news/details/compounded-weight-loss-drugs-are-a-growing-problem-for-state-regulators>. Accessed March, 2023.

National Institutes of Health (NIH), Office of Research on Women's Health. Sex and Gender. 2019. Available at: <https://orwh.od.nih.gov/sex-gender>. Accessed March 2025.

National Institutes of Health (NIH). What Are Overweight and Obesity? 2022. Available at: <https://www.nhlbi.nih.gov/health/overweight-and-obesity>. Accessed March 2025.

National Institutes of Health (NIH). Health Risks of Overweight and Obesity. 2023. Available at: <https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/health-risks>. Accessed March 2025.

Newcomer LN, Weininger R, Carlson RW. Transforming prior authorization to decision support. *Journal of Oncology Practice*. 2017;13(1):e57-e61. doi:10.1200/JOP.2016.015198

Nichols GA, Hillier TA, Brown JB. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. *The American Journal of Medicine*. 2008;121(6):519-524.

O'Connor EA, Evans CV, Burda BU, Walsh ES, Eder M, Lozano P. Screening for obesity and intervention for weight management in children and adolescents: evidence report and systematic review for the US Preventive Services Task Force. *JAMA*. 2017;317(23):2427-2444.

- Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. *New England Journal of Medicine*. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027
- Pharmacy Benefits Management Institute (PBMI). 2014-2015 Prescription Drug Benefit Cost and Plan Design Report. Plano, TX: PBMI; 2015.
- Pharmacy Benefits Management Institute (PBMI). 2018 Trends in Specialty Drug Benefits Report. Plano, TX: PBMI; 2018.
- Qin W, Yang J, Deng C, Ruan Q, Duan K. Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: an updated systematic review and meta-analysis including the 2-year STEP 5 trial. *Diabetes, Obesity & Metabolism*. 2024;26(3):911-923. doi:10.1111/dom.15386
- Resneck JS. Refocusing medication prior authorization on its intended purpose. *JAMA*. 2020;323(8):703-704.
- Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and reinitiation of dual labeled GLP-1 receptor agonists among US adults with overweight or obesity. *JAMA Network Open*. 2025;8(1):e2457349. doi: 10.1001/jamanetworkopen.2024.57349
- Sandsdal RM, Juhl CR, Jensen SBK, et al. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. *Cardiovascular Diabetology*. 2023;22(1):41. doi:10.1186/s12933-023-01765-z
- Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, Lam CSP, Lopes RD, McMurray JJV, Pratley RE, Rosenstock J, Gerstein HC. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. *Lancet Diabetes Endocrinology*. 2021;9:653-662.
- Schofield JD, Liu Y, Rao-Balakrishna P, Malik RA, Soran H. Diabetes dyslipidemia. *Diabetes Therapy*. 2016;7(2):203-219. doi:10.1007/s13300-016-0167-x
- Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. *Journal of Diabetes Investigation*. 2010;1(1-2):8-23. doi: 10.1111/j.2040-1124.2010.00022.x
- Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. *Lancet*. 2024;403(10434):e21-e31. doi:10.1016/S0140-6736(24)00351-9
- Silverii GA, Monami M, Gallo M, et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials. *Diabetes Obesity & Metabolism*. 2024;26(3):891-900. doi:10.1111/dom.15382
- Stokes A, Collins JM, Grant BF, et al. Prevalence and determinants of engagement with obesity care in the United States. *Obesity (Silver Spring)*. 2018;26(5):814-818. doi:10.1002/oby.22173
- Tronieri JS, Wadden TA, Walsh O, et al. Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial. *International Journal of Obesity (London)*. 2020;44(2):353-361. doi:10.1038/s41366-019-0348-6.
- U.S. Food and Drug Administration (FDA). Drugs@FDA. Available at: <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=browseByLetter.page&productLetter=C&ai=0>. Accessed March 2025a.
- U.S. Food and Drug Administration (FDA). FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. March 10, 2025b. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize>. Accessed March 2025.
- U.S. Food and Drug Administration (FDA). Human Drug Compounding. December 18, 2024. Available at: <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding>. Accessed March, 2025.
- U.S. Office of Personnel Management (OPM). Healthcare and Insurance. Letter Number 2023-01. Subject: Prevention and Treatment of Obesity. January 18, 2023. Available at: <https://www.opm.gov/healthcare-insurance/healthcare/carriers/2023/2023-01.pdf>. Accessed March 11, 2025.

- U.S. Preventive Services Task Force (USPSTF), Curry SJ, Krist AH, Owens DK, et al. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: U.S. Preventive Services Task Force Recommendation Statement. *JAMA*. 2018;320(11):1163-1171. doi:10.1001/jama.2018.13022
- Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: a review. *Epilepsy Research*. 2011;95(3):189-199. doi:10.1016/j.eplepsyres.2011.05.014
- Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. *JAMA*. 1999;282(22):2131-2135. doi:10.1001/jama.282.22.2131
- Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. *JAMA*. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831
- Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. *Lancet*. 2011;378:815-825. doi:10.1016/S0140-6736(11)60814-3
- Washington TB, Johnson VR, Kendrick K, Ibrahim AA, Tu L, Sun K, Stanford FC. Disparities in access and quality of obesity care. *Gastroenterology Clinics*. 2023;52(2):429-441.
- Waters H, Graf M. America's Obesity Crisis: The Health and Economic Costs of Excess Weight. Santa Monica, CA: *Milken Institute*; 2018. Available at: https://milkeninstitute.org/sites/default/files/reports-pdf/Mi-Americas-Obesity-Crisis-WEB_2.pdf. Accessed on April 21, 2025.
- Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity. *New England Journal of Medicine*. 2022;387(24):2245-2257. doi:10.1056/NEJMoa2208601
- Wilkinson L, Holst-Hansen T, Laursen PN, Rinnov AR, Batterham RL, Garvey WT. Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity. *Obesity (Silver Spring)*. 2023;31(9):2249-2259. doi:10.1002/oby.23842
- Williams E, Rudowitz R, Bell C. Medicaid Coverage of and Spending on GLP-1s. November 4, 2024. Available at: <https://www.kff.org/medicaid/issue-brief/medicaid-coverage-of-and-spending-on-glp-1s/>. Accessed March 11, 2025.
- Wyatt R, Laderman M, Botwinick L, Mate K, Whittington J. Achieving Health Equity: A Guide for Health Care Organizations. IHI White Paper. Cambridge, MA: Institute for Healthcare Improvement; 2016.
- Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. *Signal Transduction and Targeted Therapy*. 2024;9:234. <https://doi.org/10.1038/s41392-024-01931-z>

California Health Benefits Review Program

Committees and Staff

CHBRP is an independent program administered and housed by the University of California, Berkeley, under the Office of the Vice Chancellor for Research. A group of faculty, researchers, and staff complete the analysis that informs CHBRP reports. The CHBRP **Faculty Task Force** comprises rotating senior faculty from University of California (UC) campuses. In addition to these representatives, there are other ongoing researchers and analysts who are **Task Force Contributors** to CHBRP from UC that conduct much of the analysis. The **CHBRP staff** works with Task Force members in preparing parts of the analysis, and manages external communications, including those with the California Legislature. As required by CHBRP's authorizing legislation, UC contracts with an independent actuarial firm, **Milliman, Inc.**, to assist in assessing the financial impact of each legislative proposal mandating or repealing a health insurance benefit. The **National Advisory Council** provides expert reviews of draft analyses and offers general guidance on the program to CHBRP staff and the Faculty Task Force. Information on CHBRP's analysis methodology, authorizing statute, as well as all CHBRP reports and other publications, are available at chbrp.org.

CHBRP Staff

Garen Corbett, MS, Director
Adara Citron, MPH, Associate Director
An-Chi Tsou, PhD, Principal Policy Analyst
Anna Pickrell, MPH Principal Policy Analyst
Karen Shore, PhD, Contractor*
Nisha Kurani, MPP, Contractor*

*Independent Contractor working with CHBRP to support analyses and other projects.

Faculty Task Force

Paul Brown, PhD, University of California, Merced
Timothy T. Brown, PhD, University of California, Berkeley
Shana Charles, PhD, MPP, University of California, Los Angeles, and California State University, Fullerton
Janet Coffman, MA, MPP, PhD, *Vice Chair for Medical Effectiveness*, University of California, San Francisco
Todd Gilmer, PhD, University of California, San Diego
Sylvia Guendelman, PhD, LCSW, University of California, Berkeley
Elizabeth Magnan, MD, PhD, *Vice Chair for Medical Effectiveness and Public Health*, University of California, Davis
Sara McMenamin, PhD, *Vice Chair for Medical Effectiveness and Public Health*, University of California, San Diego
Joy Melnikow, MD, MPH, University of California, Davis
Aimee Moulin, MD, University of California, Davis
Jack Needleman, PhD, University of California, Los Angeles
Mark A. Peterson, PhD, University of California, Los Angeles
Nadereh Pourat, PhD, *Vice Chair for Cost*, University of California, Los Angeles
Dylan Roby, PhD, University of California, Irvine
Marilyn Stebbins, PharmD, University of California, San Francisco
Jonathan Watanabe, PharmD, MS, PhD, University of California, San Francisco

Task Force Contributors

Bethney Bonilla-Herrera, MA, University of California, Davis
Danielle Casteel, MA, University of California, San Diego
Margaret Fix, MPH, University of California, San Francisco
Carlos Gould, PhD, University of California, San Diego
Julia Huerta, BSN, RN, MPH, University of California, Davis
Michelle Keller, PhD, MPH, University of California, Los Angeles, and University of Southern California

Thet Nwe Myo Khin, MPH, University of California, San Diego
Xenia Mendez, MPH, University of California, San Francisco
Jacqueline Miller, University of California, San Francisco
Marykate Miller, MS, University of California, Davis
Katrine Padilla, MPP, University of California, Davis
Kyoko Peterson, MPH, University of California, San Francisco
Amy Quan, MPH, University of California, San Francisco
Dominique Ritley, MPH, University of California, Davis
Riti Shimkhada, PhD, University of California, Los Angeles
Meghan Soulsby Weyrich, MPH, University of California, Davis
Steven Tally, PhD, University of California, San Diego

National Advisory Council

Lauren LeRoy, PhD, Strategic Advisor, L. LeRoy Strategies, *Chair*
Stuart H. Altman, PhD, Professor of National Health Policy, Brandeis University, Waltham, MA
Deborah Chollet, PhD, Senior Fellow, Mathematica Policy Research, Washington, DC
Allen D. Feezor, Former Deputy Secretary for Health Services, North Carolina Department of Health and Human Services, Raleigh, NC
Charles "Chip" Kahn, MPH, President and CEO, Federation of American Hospitals, Washington, DC
Jeffrey Lerner, PhD, President Emeritus, ECRI Institute Headquarters, Plymouth Meeting, PA; Adjunct Senior Fellow, Leonard Davis Institute of Health Economics, University of Pennsylvania
Donald E. Metz, Executive Editor, *Health Affairs*, Washington, DC
Dolores Mitchell, (Retired) Executive Director, Group Insurance Commission, Boston, MA
Marilyn Moon, PhD, (Retired) Senior Fellow, American Institutes for Research, Washington, DC
Rachel Nuzman, MPH, Senior Vice President for Federal and State Health Policy, The Commonwealth Fund, New York, NY
Carolyn Pare, (Retired) President and CEO, Minnesota Health Action Group, Bloomington, MN
Osula Evadne Rushing, MPH, Senior Vice President for Strategic Engagement, KFF, Washington, DC
Ruchika Talwar, MD, MMHC, Assistant Professor Department of Urology and Medical Director Episodes of Care, Population Health, Vanderbilt University Medical Center
Alan Weil, JD, MPP, Senior Vice President for Public Policy, AARP, Washington, DC

Acknowledgments

CHBRP gratefully acknowledges the efforts of the team contributing to this analysis:

Amy Quan, MPH, of the University of California, San Francisco, prepared the medical effectiveness analysis. Bruce Abbott, MLS, of the University of California, Davis, conducted the literature search. Sara McMenamin, PhD, Thet Nwe Myo Khin, MPH, and Katherine Cha, all of the University of California, San Diego, prepared the public health impact analysis. Dylan Roby, PhD, of the University of California, Irvine, prepared the cost impact analysis. Andy Dressler, ASA, MAAA, and John Rogers, ASA, MAAA, MS, of Milliman, provided actuarial analysis. Diana Thiara, MD, and Grace Lin, MD, of the University of California, San Francisco, provided technical assistance with the literature search and expert input on the analytic approach. An-Chi Tsou, PhD, of CHBRP staff, prepared the Policy Context and synthesized the individual sections into a single report. A subcommittee of CHBRP's National Advisory Council (see previous page of this report) and a member of the CHBRP Faculty Task Force, Jonathan H. Watanabe, PharmD, MS, PhD, of the University of California, San Francisco, reviewed the analysis for its accuracy, completeness, clarity, and responsiveness to the Legislature's request.

CHBRP assumes full responsibility for the report and the accuracy of its contents. All CHBRP bill analyses and other publications are available at chbrp.org.

Garen Corbett, MS, Director

Please direct any questions concerning this document to: California Health Benefits Review Program, MC 3116, Berkeley, CA 94720-3116; info@chbrp.org; or chbrp.org.

Suggested Citation

California Health Benefits Review Program (CHBRP). (2025). *Analysis of California Senate Bill 535 Obesity Treatment Parity Act*. Berkeley, CA